
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Impact of PNPLA3 I148M on Drug‐Induced Hepatocellular Liver Injury: A Systematic Review and Meta‐Analysis - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="D2E481DE8AEECAE30581DE00096FE87B.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="blackwellopen">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12375943/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Liver International">
<meta name="citation_title" content="Impact of PNPLA3 I148M on Drug‐Induced Hepatocellular Liver Injury: A Systematic Review and Meta‐Analysis">
<meta name="citation_author" content="Alexandra Gatzios">
<meta name="citation_author_institution" content="In Vitro Liver Disease Modelling Team, Department of In Vitro Toxicology &amp; Dermato‐Cosmetology, Faculty of Medicine &amp; Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium">
<meta name="citation_author" content="Lorna Marchandise">
<meta name="citation_author_institution" content="In Vitro Liver Disease Modelling Team, Department of In Vitro Toxicology &amp; Dermato‐Cosmetology, Faculty of Medicine &amp; Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium">
<meta name="citation_author" content="Hannes Hagström">
<meta name="citation_author_institution" content="Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden">
<meta name="citation_author_institution" content="Division of Hepatology, Department of Upper GI, Karolinska University Hospital, Stockholm, Sweden">
<meta name="citation_author" content="Jörn M Schattenberg">
<meta name="citation_author_institution" content="Department of Medicine II, University Medical Center Homburg, Homburg and Saarland University, Saarbrücken, Germany">
<meta name="citation_author" content="Robim M Rodrigues">
<meta name="citation_author_institution" content="In Vitro Liver Disease Modelling Team, Department of In Vitro Toxicology &amp; Dermato‐Cosmetology, Faculty of Medicine &amp; Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium">
<meta name="citation_author" content="Tamara Vanhaecke">
<meta name="citation_author_institution" content="In Vitro Liver Disease Modelling Team, Department of In Vitro Toxicology &amp; Dermato‐Cosmetology, Faculty of Medicine &amp; Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium">
<meta name="citation_author" content="Joost Boeckmans">
<meta name="citation_author_institution" content="In Vitro Liver Disease Modelling Team, Department of In Vitro Toxicology &amp; Dermato‐Cosmetology, Faculty of Medicine &amp; Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium">
<meta name="citation_publication_date" content="2025 Aug 25">
<meta name="citation_volume" content="45">
<meta name="citation_issue" content="9">
<meta name="citation_firstpage" content="e70287">
<meta name="citation_doi" content="10.1111/liv.70287">
<meta name="citation_pmid" content="40851509">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12375943/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12375943/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12375943/pdf/LIV-45-0.pdf">
<meta name="description" content="The role of the patatin‐like phospholipase domain‐containing protein 3 (PNPLA3)‐I148M variant in drug‐induced liver injury (DILI) remains unclear. This systematic review with meta‐analysis investigated whether carriage of PNPLA3 I148M may contribute ...">
<meta name="og:title" content="Impact of PNPLA3 I148M on Drug‐Induced Hepatocellular Liver Injury: A Systematic Review and Meta‐Analysis">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="The role of the patatin‐like phospholipase domain‐containing protein 3 (PNPLA3)‐I148M variant in drug‐induced liver injury (DILI) remains unclear. This systematic review with meta‐analysis investigated whether carriage of PNPLA3 I148M may contribute ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12375943/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12375943">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1111/liv.70287"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/LIV-45-0.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12375943%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12375943/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12375943/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12375943/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-blackwellopen.png" alt="Wiley Open Access Collection logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Wiley Open Access Collection" title="Link to Wiley Open Access Collection" shape="default" href="https://doi.org/10.1111/liv.70287" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Liver Int</button></div>. 2025 Aug 25;45(9):e70287. doi: <a href="https://doi.org/10.1111/liv.70287" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1111/liv.70287</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Liver%20Int%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liver%20Int%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Liver%20Int%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Liver%20Int%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Impact of PNPLA3 I148M on Drug‐Induced Hepatocellular Liver Injury: A Systematic Review and Meta‐Analysis</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gatzios%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Alexandra Gatzios</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Alexandra Gatzios</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>In Vitro Liver Disease Modelling Team, Department of In Vitro Toxicology &amp; Dermato‐Cosmetology, Faculty of Medicine &amp; Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gatzios%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Alexandra Gatzios</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Marchandise%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Lorna Marchandise</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Lorna Marchandise</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>In Vitro Liver Disease Modelling Team, Department of In Vitro Toxicology &amp; Dermato‐Cosmetology, Faculty of Medicine &amp; Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Marchandise%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Lorna Marchandise</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hagstr%C3%B6m%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Hannes Hagström</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Hannes Hagström</span></h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden</div>
<div class="p">
<sup>
<sup>3</sup>
</sup>Division of Hepatology, Department of Upper GI, Karolinska University Hospital, Stockholm, Sweden</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hagstr%C3%B6m%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Hannes Hagström</span></a>
</div>
</div>
<sup>2,</sup><sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Schattenberg%20JM%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Jörn M Schattenberg</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Jörn M Schattenberg</span></h3>
<div class="p">
<sup>
<sup>4</sup>
</sup>Department of Medicine II, University Medical Center Homburg, Homburg and Saarland University, Saarbrücken, Germany</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Schattenberg%20JM%22%5BAuthor%5D" class="usa-link"><span class="name western">Jörn M Schattenberg</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rodrigues%20RM%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Robim M Rodrigues</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Robim M Rodrigues</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>In Vitro Liver Disease Modelling Team, Department of In Vitro Toxicology &amp; Dermato‐Cosmetology, Faculty of Medicine &amp; Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rodrigues%20RM%22%5BAuthor%5D" class="usa-link"><span class="name western">Robim M Rodrigues</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Vanhaecke%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Tamara Vanhaecke</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Tamara Vanhaecke</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>In Vitro Liver Disease Modelling Team, Department of In Vitro Toxicology &amp; Dermato‐Cosmetology, Faculty of Medicine &amp; Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Vanhaecke%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Tamara Vanhaecke</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Boeckmans%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Joost Boeckmans</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Joost Boeckmans</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>In Vitro Liver Disease Modelling Team, Department of In Vitro Toxicology &amp; Dermato‐Cosmetology, Faculty of Medicine &amp; Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Boeckmans%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Joost Boeckmans</span></a>
</div>
</div>
<sup>1</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="liv70287-aff-0001">
<sup>
<sup>1</sup>
</sup>In Vitro Liver Disease Modelling Team, Department of In Vitro Toxicology &amp; Dermato‐Cosmetology, Faculty of Medicine &amp; Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium</div>
<div id="liv70287-aff-0002">
<sup>
<sup>2</sup>
</sup>Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden</div>
<div id="liv70287-aff-0003">
<sup>
<sup>3</sup>
</sup>Division of Hepatology, Department of Upper GI, Karolinska University Hospital, Stockholm, Sweden</div>
<div id="liv70287-aff-0004">
<sup>
<sup>4</sup>
</sup>Department of Medicine II, University Medical Center Homburg, Homburg and Saarland University, Saarbrücken, Germany</div>
<div class="author-notes p">
<div class="fn" id="correspondenceTo">
<sup>*</sup><p class="display-inline">

<strong>Correspondence:</strong>
 
Alexandra Gatzios (<span>alexandra.gatzios@vub.be</span>)
</p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Revised 2025 Jul 30; Received 2025 Mar 13; Accepted 2025 Aug 5; Issue date 2025 Sep.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2025 The Author(s). <em>Liver International</em> published by John Wiley &amp; Sons Ltd.</div>
<p>This is an open access article under the terms of the <a href="https://creativecommons.org/licenses/by-nc/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc/4.0/</a> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12375943  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40851509/" class="usa-link">40851509</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>ABSTRACT</h2>
<section id="liv70287-sec-0001"><h3 class="pmc_sec_title">Background and Aims</h3>
<p>The role of the <em>patatin‐like phospholipase domain‐containing protein 3</em> (PNPLA3)‐I148M variant in drug‐induced liver injury (DILI) remains unclear. This systematic review with meta‐analysis investigated whether carriage of PNPLA3 I148M may contribute to the development of hepatocellular DILI.</p></section><section id="liv70287-sec-0002"><h3 class="pmc_sec_title">Methods</h3>
<p>Scientific databases were searched up to January 31st, 2025 for studies investigating serum transaminase elevations in response to drug treatment. Studies were included if serum transaminases were elevated in at least one genetic subgroup (II/IM/MM), and the possible presence of relevant hepatocellular DILI was estimated based on Hy's law. The meta‐analysis reported on any increase in transaminases compared to baseline levels.</p></section><section id="liv70287-sec-0003"><h3 class="pmc_sec_title">Results</h3>
<p>Eight articles covering thirteen studies with a total of 8235 patients were included in the systematic review, of which 5 studies comprising 3480 individuals were eligible for the meta‐analysis. Patients were treated with small molecules (<em>n</em> = 602), biologicals (<em>n</em> = 3221), or chemotherapeutic treatments (<em>n</em> = 4412). None of the studies reported conclusively more occurrence of relevant hepatocellular DILI based on PNPLA3 I148M carriage. The meta‐analysis suggested amplified drug‐induced transaminase elevations in response to adomeglivant and basal insulin peglispro in metabolically impaired individuals with PNPLA3‐IM/MM compared to PNPLA3‐II (odds ratio = 1.53, 95% CI = 1.22–1.92). None of the studies were primarily designed to detect the outcome of interest.</p></section><section id="liv70287-sec-0004"><h3 class="pmc_sec_title">Conclusions</h3>
<p>Low to no evidence suggests that carriage of PNPLA3 I148M confers susceptibility to develop clinically relevant hepatocellular DILI; although it may potentiate drug‐induced transaminase elevations in response to adomeglivant and basal insulin peglispro in metabolically impaired individuals.</p></section><section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> chemical and drug induced liver injury, genetics, hepatotoxicity, patatin‐like phospholipase domain‐containing protein 3, transaminases</p></section></section><hr class="headless">
<section class="bt xbox font-sm" id="liv70287-blkfxd-0001"><h2 class="obj_head">Summary.</h2>
<ul id="liv70287-list-0001" class="list" style="list-style-type:disc">
<li id="liv70287-li-0001"><p>Carriage of PNPLA3 I148M is unlikely to increase the risk of clinically relevant hepatocellular drug‐induced liver injury.</p></li>
<li id="liv70287-li-0002"><p>In metabolically impaired patients, carriage of the PNPLA3 I148M variant may confer susceptibility to develop more pronounced drug‐induced transaminase elevations in response to adomeglivant and basal insulin peglispro, which both influence lipid metabolism.</p></li>
<li id="liv70287-li-0003"><p>(Exacerbation of) underlying MASLD could have mediated the increased propensity to develop higher levels of transaminases in PNPLA3 I148M carriers in response to certain drugs.</p></li>
<li id="liv70287-li-0004"><p>Studies investigating the effect of PNPLA3 I148M on drug‐induced hepatotoxicity are scarce.</p></li>
</ul></section><section id="sec5"><h3>Abbreviations</h3>
<dl class="def-list" id="liv70287-dl-0001">
<dt id="liv70287-li-0005">ALL</dt>
<dd id="liv70287-li-0006"><p>acute lymphoblastic leukaemia</p></dd>
<dt id="liv70287-li-0007">ALP</dt>
<dd id="liv70287-li-0008"><p>alkaline phosphatase</p></dd>
<dt id="liv70287-li-0009">ALT</dt>
<dd id="liv70287-li-0010"><p>alanine aminotransferase</p></dd>
<dt id="liv70287-li-0011">AST</dt>
<dd id="liv70287-li-0012"><p>aspartate aminotransferase</p></dd>
<dt id="liv70287-li-0013">BMI</dt>
<dd id="liv70287-li-0014"><p>body mass index</p></dd>
<dt id="liv70287-li-0015">CFB</dt>
<dd id="liv70287-li-0016"><p>change from baseline</p></dd>
<dt id="liv70287-li-0017">CI</dt>
<dd id="liv70287-li-0018"><p>confidence interval</p></dd>
<dt id="liv70287-li-0019">CTCAE</dt>
<dd id="liv70287-li-0020"><p>common terminology criteria for adverse events</p></dd>
<dt id="liv70287-li-0021">DILI</dt>
<dd id="liv70287-li-0022"><p>drug‐induced liver injury</p></dd>
<dt id="liv70287-li-0023">EASL</dt>
<dd id="liv70287-li-0024"><p>European Association for the Study of the Liver</p></dd>
<dt id="liv70287-li-0025">FDR</dt>
<dd id="liv70287-li-0026"><p>false discovery rate</p></dd>
<dt id="liv70287-li-0027">IFNβ‐1α</dt>
<dd id="liv70287-li-0028"><p>interferon beta 1 alpha</p></dd>
<dt id="liv70287-li-0029">LFC</dt>
<dd id="liv70287-li-0030"><p>liver fat content</p></dd>
<dt id="liv70287-li-0031">MASLD</dt>
<dd id="liv70287-li-0032"><p>metabolic dysfunction‐associated steatotic liver disease</p></dd>
<dt id="liv70287-li-0033">NOS</dt>
<dd id="liv70287-li-0034"><p>Newcastle‐Ottawa quality assessment scale</p></dd>
<dt id="liv70287-li-0035">OR</dt>
<dd id="liv70287-li-0036"><p>odds ratio</p></dd>
<dt id="liv70287-li-0037">PNPLA3</dt>
<dd id="liv70287-li-0038"><p>patatin‐like phospholipase domain‐containing protein 3</p></dd>
<dt id="liv70287-li-0039">PRISMA</dt>
<dd id="liv70287-li-0040"><p>Preferred Reporting Items for Systematic reviews and Meta‐Analyses</p></dd>
<dt id="liv70287-li-0041">RCT</dt>
<dd id="liv70287-li-0042"><p>randomised controlled trial</p></dd>
<dt id="liv70287-li-0043">RoB 2</dt>
<dd id="liv70287-li-0044"><p>revised Cochrane Risk‐of‐Bias tool for randomised trials</p></dd>
<dt id="liv70287-li-0045">ROBINS‐I</dt>
<dd id="liv70287-li-0046"><p>Risk Of Bias In Non‐randomised Studies—of Interventions assessment tool</p></dd>
<dt id="liv70287-li-0047">SMD</dt>
<dd id="liv70287-li-0048"><p>standardised mean difference</p></dd>
<dt id="liv70287-li-0049">T2DM</dt>
<dd id="liv70287-li-0050"><p>type 2 diabetes mellitus</p></dd>
<dt id="liv70287-li-0051">ULN</dt>
<dd id="liv70287-li-0052"><p>upper limit of normal</p></dd>
<dt id="liv70287-li-0053">VLDL</dt>
<dd id="liv70287-li-0054"><p>very low density lipoprotein</p></dd>
</dl></section><section id="liv70287-sec-0008"><h2 class="pmc_sec_title">1. Introduction</h2>
<p>Drug‐induced liver injury (DILI) can result in acute liver failure, making it a relevant cause of liver‐related death. The global incidence of DILI is unclear but prospective studies from France and Iceland reported annual incidences in the general population of 13.9 and 19.1 per 100 000 inhabitants [<a href="#liv70287-bib-0001" class="usa-link" aria-describedby="liv70287-bib-0001">1</a>, <a href="#liv70287-bib-0002" class="usa-link" aria-describedby="liv70287-bib-0002">2</a>]. DILI is a challenging clinical condition responsible for roughly half of the cases of acute liver failure reported in the USA and Western Europe [<a href="#liv70287-bib-0003" class="usa-link" aria-describedby="liv70287-bib-0003">3</a>, <a href="#liv70287-bib-0004" class="usa-link" aria-describedby="liv70287-bib-0004">4</a>], and accounts for 8% of liver transplantations in Europe [<a href="#liv70287-bib-0005" class="usa-link" aria-describedby="liv70287-bib-0005">5</a>].</p>
<p>Further, DILI is amongst the leading reasons for late‐stage discontinuation of agents during clinical trials or post‐marketing regulatory actions. Specifically, hepatotoxicity accounted for one in every four terminations during clinical development and one third of market withdrawals between 1975 and 2007 in the USA [<a href="#liv70287-bib-0006" class="usa-link" aria-describedby="liv70287-bib-0006">6</a>]. The lack of specific, validated biomarkers to predict DILI complicates its management during clinical trials, where monitoring of alanine and aspartate aminotransferases (ALT and AST) in serum remains the most accessible and recommended approach to evaluate potential hepatic injury in study participants. According to the guidelines of the European Association for the Study of the Liver (EASL), DILI should be suspected in a clinical trial when ALT and/or AST levels were normal at baseline and exceed 3‐fold the upper limit of normal (ULN) during treatment [<a href="#liv70287-bib-0007" class="usa-link" aria-describedby="liv70287-bib-0007">7</a>]. Apart from transaminase elevations &gt; 3‐fold the ULN, Hy's law, which serves as an indicator that a drug is likely to cause severe hepatocellular DILI, additionally considers elevations of total serum bilirubin &gt; 2‐fold, and the elevations in AST/ALT should have occurred in the absence of elevated serum alkaline phosphatase or other alternative explanations [<a href="#liv70287-bib-0008" class="usa-link" aria-describedby="liv70287-bib-0008">8</a>].</p>
<p>The underlying mechanisms culminating in DILI are often of multifactorial nature and involve an interplay between both characteristics of the DILI‐causing agent and patient‐related factors including age, sex, environment and genetics [<a href="#liv70287-bib-0009" class="usa-link" aria-describedby="liv70287-bib-0009">9</a>]. In this context, a single nucleotide polymorphism in <em>patatin‐like phospholipase domain‐containing 3</em> (PNPLA3), PNPLA3 I148M, has been robustly associated with metabolic dysfunction‐associated steatotic liver disease (MASLD) susceptibility and progression [<a href="#liv70287-bib-0010" class="usa-link" aria-describedby="liv70287-bib-0010">10</a>, <a href="#liv70287-bib-0011" class="usa-link" aria-describedby="liv70287-bib-0011">11</a>], and also with advanced liver disease due to other aetiologies [<a href="#liv70287-bib-0012" class="usa-link" aria-describedby="liv70287-bib-0012">12</a>]. PNPLA3 I148M has also been linked to increased serum ALT and AST levels, and in vitro studies suggest that it may also impact the drug metabolising capacity of hepatocytes, possibly altering their sensitivity to hepatotoxicity [<a href="#liv70287-bib-0010" class="usa-link" aria-describedby="liv70287-bib-0010">10</a>, <a href="#liv70287-bib-0013" class="usa-link" aria-describedby="liv70287-bib-0013">13</a>, <a href="#liv70287-bib-0014" class="usa-link" aria-describedby="liv70287-bib-0014">14</a>]. While a recent systematic review showed that carriage of PNPLA3 I148M may influence the response to treatment for hepatic steatosis, its potential impact on the susceptibility to develop DILI remains elusive [<a href="#liv70287-bib-0015" class="usa-link" aria-describedby="liv70287-bib-0015">15</a>].</p>
<p>This systematic review with meta‐analysis investigated whether hetero‐ or homozygous carriage of the PNPLA3 I148M variant may potentiate drug‐induced hepatocellular liver injury.</p></section><section id="liv70287-sec-0009"><h2 class="pmc_sec_title">2. Methods</h2>
<p>The Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) checklist is available as a supplement.</p>
<section id="liv70287-sec-0010"><h3 class="pmc_sec_title">2.1. Eligibility Criteria</h3>
<p>Study eligibility criteria are given in Table <a href="#liv70287-supitem-0001" class="usa-link">S1</a>. Clinical studies were included from full‐text research papers or conference proceedings, written in English. Studies were eligible if serum aminotransferase test disturbances were detected during drug treatment for any non‐hepatic disease in at least one subgroup of PNPLA3 I148M (II/IM/MM). Studies were excluded when no genotyping for PNPLA3 I148M was done, no serum aminotransferase tests were performed after treatment, or when the agent could be classified as a dietary supplement according to European (Directive 2002/46/EC) or USA law (Dietary Supplement Health and Education Act of 1994).</p></section><section id="liv70287-sec-0011"><h3 class="pmc_sec_title">2.2. Information Sources</h3>
<p>MEDLINE, Cochrane Library and Web of Science were searched for publications up to January 31st, 2025.</p></section><section id="liv70287-sec-0012"><h3 class="pmc_sec_title">2.3. Search Strategy</h3>
<p>MEDLINE: (((PNPLA3) OR (patatin‐like phospholipase domain–containing 3) OR (adiponutrin)) AND (rs738409)) AND ((DILI) OR (drug induced liver injury) OR (liver toxicity) OR (hepatotoxicity)).</p>
<p>Cochrane Library: ‘PNPLA3’ AND ‘rs738409’ AND (‘Drug induced liver injury’ OR ‘DILI’ OR ‘liver toxicity’ OR ‘aminotransferases’) + filter Trials.</p>
<p>Web of Science: AB = (PNPLA3 OR patatin‐like phospholipase domain‐containing protein 3 OR adiponutrin) AND AB = (DILI OR drug‐induced liver injury OR liver toxicity OR hepatotoxicity) + filter Review article (exclude).</p>
<p>Additionally, citation searching was performed to identify any other reports that could meet the predefined eligibility criteria.</p></section><section id="liv70287-sec-0013"><h3 class="pmc_sec_title">2.4. Selection Process</h3>
<p>Duplicates were manually removed from the search results, and pre‐screening of titles, abstracts and keywords was done to identify potentially relevant records based on study type and the mentioning of the terms ‘PNPLA3’ and ‘DILI’, or synonyms thereof. Remaining full‐text reports were subsequently assessed for all eligibility criteria listed in Table <a href="#liv70287-supitem-0001" class="usa-link">S1</a>. The search was conducted independently by two researchers; inconsistencies were discussed to reach a consensus. A third researcher was available for discussion in case consensus could not be reached by the two primary researchers.</p></section><section id="liv70287-sec-0014"><h3 class="pmc_sec_title">2.5. Data Collection Process</h3>
<p>A premade extraction sheet in Microsoft Excel was used for data collection by two independent researchers. The collected data were compared, and inconsistencies were discussed to reach a consensus. A third researcher was available for discussion in case consensus could not be reached by the two primary researchers.</p></section><section id="liv70287-sec-0015"><h3 class="pmc_sec_title">2.6. Data Items</h3>
<section id="liv70287-sec-0016"><h4 class="pmc_sec_title">2.6.1. Outcomes</h4>
<p>The primary outcome was the effect of PNPLA3 I148M IM/MM vs II genotypes on treatment‐related increase of ALT and/or AST levels. Secondary outcomes were the occurrence of hepatocellular DILI based on thresholds defined by Hy's law [<a href="#liv70287-bib-0008" class="usa-link" aria-describedby="liv70287-bib-0008">8</a>]: ALT and/or AST ≥ 3‐fold ULN (or 3‐fold the pre‐existing level) and total bilirubin &gt; 2‐fold ULN without alkaline phosphatase (ALP) elevation or any alternative explanation; and the risks of serum transaminase elevation and hepatocellular DILI based on treatment type by PNPLA3 genotype (IM/MM vs II).</p>
<p>Data were collected on the outcome of serum aminotransferases (enzyme(s) tested, numerical outcome/change from baseline, <em>p</em>‐value, odds ratio). If available, bilirubin and alkaline phosphatase levels were also noted. If applicable, specific criteria used for classification of the observed hepatotoxicity were also noted.</p></section><section id="liv70287-sec-0017"><h4 class="pmc_sec_title">2.6.2. Other Variables</h4>
<p>Report details (first author, year of publication), study details (design, duration, participating countries, registration number), patient characteristics (disease, age, sex, body mass index (BMI), PNPLA3 I148M genotype) and intervention details (intervention, treatment arms, dosage, frequency, duration, number of patients per group) were collected.</p></section></section><section id="liv70287-sec-0018"><h3 class="pmc_sec_title">2.7. Study Risk of Bias Assessment</h3>
<p>Risk of bias was assessed independently by two researchers using the revised Cochrane Risk‐of‐Bias tool for randomised trials (RoB 2) [<a href="#liv70287-bib-0016" class="usa-link" aria-describedby="liv70287-bib-0016">16</a>], the Risk of Bias in Non‐randomised Studies—of Interventions (ROBINS‐I) assessment tool (version for cohort‐type studies) [<a href="#liv70287-bib-0017" class="usa-link" aria-describedby="liv70287-bib-0017">17</a>] and the Newcastle‐Ottawa quality assessment scale (NOS) for case‐control studies [<a href="#liv70287-bib-0018" class="usa-link" aria-describedby="liv70287-bib-0018">18</a>]. Inconsistencies were discussed to reach a consensus, and a third researcher was available for discussion in case consensus could not be reached by the two primary researchers.</p></section><section id="liv70287-sec-0019"><h3 class="pmc_sec_title">2.8. Effect Measures</h3>
<p>A meta‐analysis was performed for the composite outcome of increased serum ALT and/or AST level after treatment with a small molecule, biological or chemotherapy protocol in PNPLA3 IM/MM carriers compared to PNPLA3 II carriers. The effect measure used in the meta‐analysis was the corresponding odds ratio (OR) and its 95% confidence interval (CI).</p></section><section id="liv70287-sec-0020"><h3 class="pmc_sec_title">2.9. Synthesis Methods</h3>
<p>All studies that met the eligibility criteria were included in the narrative synthesis of results. When studies reported on ALT and/or AST elevations ≥ 3‐fold ULN, but without additional information to apply Hy's law, the impact of PNPLA3 I148M was graded as ‘possibly contributing to relevant hepatocellular DILI’. When no cutoff data for ALT and/or AST was available and only minor increases in their levels were observed without any other notice of severe hepatocellular liver injury, the effect of PNPLA3 I148M was considered as ‘unlikely contributing to relevant hepatocellular DILI’.</p>
<p>For the meta‐analysis, only studies that either reported an OR and its 95% CI from a dominant (IM/MM vs. II) logistic regression model regarding ALT and/or AST, or reported sufficient data allowing calculation of the standardised mean difference (SMD) as Cohen's <em>d</em> between PNPLA3 IM/MM and II groups, were eligible for inclusion [<a href="#liv70287-bib-0019" class="usa-link" aria-describedby="liv70287-bib-0019">19</a>]. Studies were excluded from the meta‐analysis if baseline ALT and/or AST levels were not accounted for.</p>
<p>Where ORs could not be directly extracted from the publications or Appendix <a href="#liv70287-supitem-0001" class="usa-link">S1</a>, the SMD (Cohen's <em>d</em>) was calculated using the least squares mean values reported for the change from baseline (CFB) after treatment in PNPLA3 IM/MM and PNPLA3 II individuals. From the SMD, the lnOR and its 95% CI were subsequently calculated and transformed to OR and its 95% CI [<a href="#liv70287-bib-0019" class="usa-link" aria-describedby="liv70287-bib-0019">19</a>]. The input data used for the meta‐analysis is summarised in Table <a href="#liv70287-supitem-0001" class="usa-link">S2</a>.</p>
<p>Meta‐analysis was performed in R (version 4.4.2) using the meta package (version 8.0–1) [<a href="#liv70287-bib-0020" class="usa-link" aria-describedby="liv70287-bib-0020">20</a>]. A random effects model was fitted, and heterogeneity between the studies was explored by subgroup analysis based on treatment type and by using Cochran's Q, Higgins &amp; Thompson's <em>I</em>
<sup>2</sup> index and tau‐squared (τ<sup>2</sup>) metrics. Univariate meta‐regression was performed for the mean difference between the PNPLA3 IM/MM and PNPLA3 II groups in baseline age, proportion of males, BMI, %Hb1Ac, duration of T2DM, serum triglycerides and transaminase levels. In the subset of studies for which liver fat content (LFC) measurements and CFB in LFC, triglycerides and %Hb1Ac were available in both PNPLA3 IM/MM and II genetic subgroups, meta‐regression was also performed using the mean difference of these factors as covariates. The Benjamini‐Hochberg method for multiple comparisons was applied to control the false discovery rate (FDR) and adjusted <em>p</em> was considered significant when &lt; 0.05. Publication bias was assessed through a trim‐and‐fill contour‐enhanced funnel plot. The results from the meta‐analysis were presented in a forest plot.</p></section><section id="liv70287-sec-0021"><h3 class="pmc_sec_title">2.10. Reporting Bias Assessment</h3>
<p>Pre‐registration of the study protocol in a publicly accessible registry and pre‐specification of genetic subgroup analysis for PNPLA3 I148M was evaluated for all included studies as a measure for reporting bias.</p></section><section id="liv70287-sec-0022"><h3 class="pmc_sec_title">2.11. Certainty Assessment</h3>
<p>All included studies were discussed in the context of their risk of bias assessments, meaning that outcomes from studies with intermediate or high risk of bias were nuanced using that perspective during the narrative synthesis of results. For the meta‐analysis, every study was weighted according to its 95% CI; based thereon, a proportional symbol size was given in the summarising forest plot.</p></section></section><section id="liv70287-sec-0023"><h2 class="pmc_sec_title">3. Results</h2>
<section id="liv70287-sec-0024"><h3 class="pmc_sec_title">3.1. Study Selection</h3>
<p>Thirty‐five unique records were retrieved based on the pre‐defined search criteria, and 27 records were excluded after pre‐screening for keywords. The full texts of the remaining eight reports were assessed for the in‐ and exclusion criteria (Table <a href="#liv70287-supitem-0001" class="usa-link">S1</a>), after which two records were excluded. Five additional records were identified through citation searching and retrieved for full‐text screening, of which two were retained. Overall, eight full‐text reports covering thirteen unique studies were included in the systematic review (Figure <a href="#liv70287-supitem-0001" class="usa-link">S1</a>), of which five accounted for baseline transaminase levels, which were included in the meta‐analysis.</p></section><section id="liv70287-sec-0025"><h3 class="pmc_sec_title">3.2. Study Characteristics</h3>
<p>Study characteristics are summarised in Table <a href="#liv70287-tbl-0001" class="usa-link">1</a>. From the thirteen unique studies, Liu et al. [<a href="#liv70287-bib-0027" class="usa-link" aria-describedby="liv70287-bib-0027">27</a>] combined the randomised TOTXV and TOTXVI studies into one discovery cohort; therefore, these studies are discussed as one cohort. Liu et al. also reported on a replication cohort that is the randomised controlled trial (RCT) AALL0232. The report by Guzman et al. [<a href="#liv70287-bib-0022" class="usa-link" aria-describedby="liv70287-bib-0022">22</a>] covered a randomised crossover study (GLDI) and a RCT (GLDJ), and the report by Pillai et al. [<a href="#liv70287-bib-0025" class="usa-link" aria-describedby="liv70287-bib-0025">25</a>] included three RCTs, namely IMAGINE‐2, IMAGINE‐4 and IMAGINE‐5. Further, Yang et al. [<a href="#liv70287-bib-0028" class="usa-link" aria-describedby="liv70287-bib-0028">28</a>] included two studies, the RCTs AALL0232 and AALL0434, and the remaining reports yielded one study each. Two of these studies, by Feagins et al. [<a href="#liv70287-bib-0024" class="usa-link" aria-describedby="liv70287-bib-0024">24</a>] and Sundbaum et al. [<a href="#liv70287-bib-0021" class="usa-link" aria-describedby="liv70287-bib-0021">21</a>], were case–control studies and another two studies, by Capone et al. [<a href="#liv70287-bib-0023" class="usa-link" aria-describedby="liv70287-bib-0023">23</a>] and Gutierrez‐Camino et al. [<a href="#liv70287-bib-0026" class="usa-link" aria-describedby="liv70287-bib-0026">26</a>], were retrospective cohort studies. The duration of treatment covered by the studies varied from 4 weeks to 12 months, with some treatments running for several years.</p>
<section class="tw xbox font-sm" id="liv70287-tbl-0001"><h4 class="obj_head">TABLE 1.</h4>
<div class="caption p"><p>Included reports and studies.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1"></th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Country</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Study type</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Duration of study or follow‐up</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Total number of patients</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Liver enzymes outcome measure</th>
</tr></thead>
<tbody valign="top">
<tr><td align="left" colspan="6" valign="top" rowspan="1">Small molecules</td></tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Sundbaum et al. 2021 [<a href="#liv70287-bib-0021" class="usa-link" aria-describedby="liv70287-bib-0021">21</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">Sweden</td>
<td align="center" valign="top" rowspan="1" colspan="1">Case–control study</td>
<td align="center" valign="top" rowspan="1" colspan="1">6 months</td>
<td align="center" valign="top" rowspan="1" colspan="1">198</td>
<td align="center" valign="top" rowspan="1" colspan="1">New ALT elevation, defined as &gt; 1.5‐fold the upper limit of normal (ULN)</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Guzman et al. 2018 (GLDI) [<a href="#liv70287-bib-0022" class="usa-link" aria-describedby="liv70287-bib-0022">22</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">USA, Czech Republic, Mexico, Poland and Puerto Rico</td>
<td align="center" valign="top" rowspan="1" colspan="1">Multicentre randomised crossover study, triple masked</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 × 6 weeks with a 4‐week washout period (preceded by a 2‐week open‐label placebo lead‐in)</td>
<td align="center" valign="top" rowspan="1" colspan="1">246</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>ALT elevation at end of treatment, expressed as change from baseline (CFB) in IU/L</p>
<p>Patients with ALT &gt; 2.5‐fold ULN were excluded from the study</p>
</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Guzman et al. 2018 (GLDJ) [<a href="#liv70287-bib-0022" class="usa-link" aria-describedby="liv70287-bib-0022">22</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">USA, Greece, Puerto Rico and Taiwan</td>
<td align="center" valign="top" rowspan="1" colspan="1">Multicentre randomised, double‐blind, placebo‐ and active comparator‐controlled study</td>
<td align="center" valign="top" rowspan="1" colspan="1">12 months (6 months interim)</td>
<td align="center" valign="top" rowspan="1" colspan="1">158</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>ALT elevation at end of treatment, expressed as CFB in IU/L</p>
<p>Patients with ALT &gt; 2‐fold ULN were excluded from the study</p>
</td>
</tr>
<tr><td align="left" colspan="6" valign="top" rowspan="1">Biologicals</td></tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Capone et al. 2020 [<a href="#liv70287-bib-0023" class="usa-link" aria-describedby="liv70287-bib-0023">23</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">Italy</td>
<td align="center" valign="top" rowspan="1" colspan="1">Retrospective multicentre cohort study</td>
<td align="center" valign="top" rowspan="1" colspan="1">Median duration of therapy 4.4 (2.1–7.8) years.</td>
<td align="center" valign="top" rowspan="1" colspan="1">113</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>New ALT and/or AST elevation exceeding the ULN, graded using Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0</p>
<p>Patients with known liver disease, other disease modifying drug treatment, or ALT/AST &gt; ULN were excluded from the study</p>
</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Feagins et al. 2015 [<a href="#liv70287-bib-0024" class="usa-link" aria-describedby="liv70287-bib-0024">24</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">The United States of America (USA)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Case–control study</td>
<td align="center" valign="top" rowspan="1" colspan="1">Variable</td>
<td align="center" valign="top" rowspan="1" colspan="1">32</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>New ALT and/or AST elevation exceeding the ULN</p>
<p>All cases have biopsy‐proven MASLD</p>
</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Pillai et al. 2018 (IMAGINE‐2) [<a href="#liv70287-bib-0025" class="usa-link" aria-describedby="liv70287-bib-0025">25</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">USA, Argentina, Australia, Brazil, Canada, Finland, Germany, Greece, Hungary, Israel, Italy, Lithuania, Mexico, New Zealand, Poland, Puerto Rico, Romania, Russia, Slovakia, South Africa, Spain, Turkey and the United Kingdom (UK)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Multicentre randomised, double‐blind, active comparator‐controlled study</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>12 months</p>
<p>(6 months interim)</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">1364</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>ALT and/or AST elevation at end of treatment, expressed as CFB in IU/L (least squares mean)</p>
<p>Patients with ALT &gt; 2.5‐fold ULN were excluded from the study</p>
</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Pillai et al. 2018 (IMAGINE‐4) [<a href="#liv70287-bib-0025" class="usa-link" aria-describedby="liv70287-bib-0025">25</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">USA, Australia, Austria, Brazil, Croatia, Czechia, Denmark, Germany, Greece, Hungary, Israel, Italy, Japan, Lithuania, Mexico, the Netherlands, Poland, Puerto Rico, Romania, Russia, Slovakia, Spain, Taiwan, Turkey and UK</td>
<td align="center" valign="top" rowspan="1" colspan="1">Multicentre randomised, quadruple‐blind, active comparator‐controlled study</td>
<td align="center" valign="top" rowspan="1" colspan="1">6 months</td>
<td align="center" valign="top" rowspan="1" colspan="1">1284</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>ALT and/or AST elevation at end of treatment, expressed as CFB in IU/L (least squares mean)</p>
<p>Patients with ALT &gt; 2.5‐fold ULN were excluded from the study</p>
</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Pillai et al. 2018 (IMAGINE‐5) [<a href="#liv70287-bib-0025" class="usa-link" aria-describedby="liv70287-bib-0025">25</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">USA, Czechia, Germany, Greece, Israel, Puerto Rico, Romania, Russia and Spain</td>
<td align="center" valign="top" rowspan="1" colspan="1">Multicentre randomised, open label, active comparator‐controlled study</td>
<td align="center" valign="top" rowspan="1" colspan="1">12 months (6 months interim)</td>
<td align="center" valign="top" rowspan="1" colspan="1">428</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>ALT and/or AST elevation at end of treatment, expressed as CFB in IU/L (least squares mean)</p>
<p>Patients with ALT &gt; 2.5‐fold ULN were excluded from the study</p>
</td>
</tr>
<tr><td align="left" colspan="6" valign="top" rowspan="1">Combinatory chemotherapy protocols</td></tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Gutierrez‐Camino et al. 2017 [<a href="#liv70287-bib-0026" class="usa-link" aria-describedby="liv70287-bib-0026">26</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">Spain</td>
<td align="center" valign="top" rowspan="1" colspan="1">Retrospective cohort study</td>
<td align="center" valign="top" rowspan="1" colspan="1">±4 weeks (induction phase)</td>
<td align="center" valign="top" rowspan="1" colspan="1">138</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>ALT and/or AST elevation at end of induction, graded by the Spanish Society of Paediatric Haematology and Oncology standards</p>
<p>No ALT/AST‐based exclusion criteria</p>
</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Liu et al. 2017 (TOTXV + TOTXVI) [<a href="#liv70287-bib-0027" class="usa-link" aria-describedby="liv70287-bib-0027">27</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">USA</td>
<td align="center" valign="top" rowspan="1" colspan="1">Cohort consisting of two randomised, open‐label studies</td>
<td align="center" valign="top" rowspan="1" colspan="1">±6 weeks (induction phase)</td>
<td align="center" valign="top" rowspan="1" colspan="1">715</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>ALT elevation at end of induction, graded using CTCAE version 3.0</p>
<p>No ALT/AST‐based exclusion criteria</p>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Liu et al. 2017 (AALL0232, induction only) [<a href="#liv70287-bib-0027" class="usa-link" aria-describedby="liv70287-bib-0027">27</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">USA, Canada, New Zealand, Switzerland and Australia</td>
<td align="center" valign="top" rowspan="1" colspan="1">Randomised, open‐label, active comparator‐controlled study</td>
<td align="center" valign="top" rowspan="1" colspan="1">±6 weeks (induction phase)</td>
<td align="center" valign="top" rowspan="1" colspan="1">2285</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>ALT elevation at end of induction, graded using CTCAE version 4.0</p>
<p>No ALT/AST‐based exclusion criteria</p>
</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yang et al. 2022 (AALL0232) [<a href="#liv70287-bib-0028" class="usa-link" aria-describedby="liv70287-bib-0028">28</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">USA, Canada, New Zealand, Switzerland and Australia</td>
<td align="center" valign="top" rowspan="1" colspan="1">Randomised, open‐label, active comparator‐controlled study</td>
<td align="center" valign="top" rowspan="1" colspan="1">Treatment duration ranged from 2.5 to 3.5 years</td>
<td align="center" valign="top" rowspan="1" colspan="1">2283</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>ALT and/or AST elevation throughout treatment protocol, graded using CTCAE version 4.0</p>
<p>No ALT/AST‐based exclusion criteria</p>
</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yang et al. 2022 (AALL0434) [<a href="#liv70287-bib-0028" class="usa-link" aria-describedby="liv70287-bib-0028">28</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">USA, Canada, New Zealand, Switzerland and Australia</td>
<td align="center" valign="top" rowspan="1" colspan="1">Randomised, open‐label, active comparator‐controlled study</td>
<td align="center" valign="top" rowspan="1" colspan="1">Treatment duration ranged from 2.5 to 3.5 years</td>
<td align="center" valign="top" rowspan="1" colspan="1">1274</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>ALT and/or AST elevation throughout treatment protocol, graded using CTCAE version 4.0</p>
<p>No ALT/AST‐based exclusion criteria</p>
</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/liv70287-tbl-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="liv70287-note-0004"><p>Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; CFB, change from baseline; CTCAE, common toxicity criteria for adverse events; UK, United Kingdom; ULN, upper limit of normal; USA, the United States of America.</p></div></div></section><p>The included studies covered a total of 8235 patients, of which 602 received treatment with a small molecule, 3221 with a biological agent, and 4412 were treated with a chemotherapy protocol consisting of multiple drugs. Patients were treated for inflammatory diseases (rheumatoid arthritis, Crohn's disease, psoriatic arthritis, ankylosing spondylitis), multiple sclerosis, type 2 diabetes mellitus (T2DM), or acute lymphoblastic leukaemia (ALL). Details of all treatments are provided in Table <a href="#liv70287-supitem-0001" class="usa-link">S3</a>. Overall, the allelic frequencies were 0.712 and 0.288 for PNPLA3 148I and 148M, respectively, and II/IM/MM genotype frequencies were 0.527/0.370/0.103. Both the allelic and genotype frequencies were similar to those reported for the general population in the 1000 Genomes Project Phase 3 [<a href="#liv70287-bib-0029" class="usa-link" aria-describedby="liv70287-bib-0029">29</a>]. Five studies were conducted in paediatric patients. Study participant characteristics are summarised in Table <a href="#liv70287-supitem-0001" class="usa-link">S4</a>.</p>
<p>Studies used various outcome measures (Table <a href="#liv70287-tbl-0001" class="usa-link">1</a>) such as ALT/AST numerically expressed as fold of the ULN or as CFB, or ALT/AST categorically expressed as a grade of hepatotoxicity according to various criteria (e.g., common terminology criteria for adverse events (CTCAE) versions 3.0 and 4.0). None of the included studies were primarily powered to detect a difference in this outcome based on PNPLA3 I148M genotype.</p></section><section id="liv70287-sec-0026"><h3 class="pmc_sec_title">3.3. Risk of Bias in Studies</h3>
<p>Results of the bias analyses are summarised in Tables <a href="#liv70287-supitem-0001" class="usa-link">S5–S7</a>. None of the studies prespecified our outcome of interest in their study protocol, resulting in some concerns of bias in the domain ‘selection of the reported result’ for all studies.</p>
<p>Some studies were assessed for risk of bias as a cohort study despite being originally randomised trials, due to their specific <em>post hoc</em> analyses resembling a cohort study design. This was the case for TOTXV + TOTXVI and AALL0232 (Liu et al. [<a href="#liv70287-bib-0027" class="usa-link" aria-describedby="liv70287-bib-0027">27</a>]), and AALL0232 and AALL0434 (Yang et al. [<a href="#liv70287-bib-0028" class="usa-link" aria-describedby="liv70287-bib-0028">28</a>]). The study by Guttierez‐Camino et al. [<a href="#liv70287-bib-0026" class="usa-link" aria-describedby="liv70287-bib-0026">26</a>] was determined to have a serious risk of confounding (Domain 1), as the report did not mention any evaluation or correction for potential confounding domains; nor did it mention the measurement or gradation of ALT levels before treatment initiation. Similarly, baseline ALT levels were unavailable for the AALL0232 study reported by Liu et al. [<a href="#liv70287-bib-0027" class="usa-link" aria-describedby="liv70287-bib-0027">27</a>] and only gradations using the CTCAE 4.0 criteria were available; thus, the analysis was performed using cases (grade &gt; 2) and controls (grade ≤ 2). Therefore, this study was considered to have a moderate risk of bias due to missing data (Domain 5). As outcome assessors could have been aware of the treatment received by the patients in all evaluated studies, the risk of bias in Domain 6 was considered moderate. Baseline transaminase levels were also not available for both the AALL0232 and AALL0434 studies as reported by Yang et al. [<a href="#liv70287-bib-0028" class="usa-link" aria-describedby="liv70287-bib-0028">28</a>], resulting in a moderate risk of bias due to missing data (Domain 5). The remaining non‐randomised study, TOTXV + TOTXVI as reported by Liu et al. [<a href="#liv70287-bib-0027" class="usa-link" aria-describedby="liv70287-bib-0027">27</a>], had a low overall risk of bias.</p>
<p>All randomised trials had a low overall risk of bias, except for the IMAGINE‐5 trial by Pillai et al. [<a href="#liv70287-bib-0025" class="usa-link" aria-describedby="liv70287-bib-0025">25</a>], which was determined to have a high risk of bias in Domain 2 due to its open‐label study design. Further, outcome assessors were also aware of the treatment received by the patients, raising some concerns of bias in Domain 4 as well.</p>
<p>Both case–control studies were determined to have some concerns of bias. In the study by Feagins et al. [<a href="#liv70287-bib-0024" class="usa-link" aria-describedby="liv70287-bib-0024">24</a>], this was mainly due to the fact that all but one of the participants were male. In the study of Sundbaum et al. [<a href="#liv70287-bib-0021" class="usa-link" aria-describedby="liv70287-bib-0021">21</a>], concerns arose from the likelihood that the study was underpowered to detect an effect of PNPLA3 I148M.</p></section><section id="liv70287-sec-0027"><h3 class="pmc_sec_title">3.4. Results of Individual Studies</h3>
<section id="liv70287-sec-0028"><h4 class="pmc_sec_title">3.4.1. Small Molecules</h4>
<p>Sundbaum et al. [<a href="#liv70287-bib-0021" class="usa-link" aria-describedby="liv70287-bib-0021">21</a>] investigated the effect of PNPLA3 I148M on ALT elevation after 6 months of methotrexate treatment for rheumatoid arthritis, and did not find a significant association between either an increase of ALT &gt; 1.5‐fold the ULN (OR = 0.3147 [0.0845–1.132], <em>p</em> = 0.0768) or peak ALT (beta estimate = −0.08791 [−0.2650–0.08913], <em>p</em> = 0.3317) (Table <a href="#liv70287-tbl-0002" class="usa-link">2</a>), although a trend towards a detrimental effect for the II group was seen. It should be noted that in this study, 50% of patients included as cases had a history of ALT elevations compared to 12.5% of the controls (<em>p</em> = 0.001) which might have biased the results. Furthermore, the study was powered at 80% to detect an OR of ±7.5 at a genome‐wide level for a marker with a minor allele frequency of 0.4. Considering the reported minor allele frequencies of 0.083 in cases and 0.206 in controls, this study was underpowered to detect more subtle effects of this specific variant [<a href="#liv70287-bib-0029" class="usa-link" aria-describedby="liv70287-bib-0029">29</a>]. Therefore, no general conclusion can be drawn regarding a possible effect of the PNPLA3 I148M variant on methotrexate‐induced ALT/AST elevations.</p>
<section class="tw xbox font-sm" id="liv70287-tbl-0002"><h5 class="obj_head">TABLE 2.</h5>
<div class="caption p"><p>Results of individual studies.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1"></th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Intervention</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Outcome measure(s) used</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Numerical outcome [brackets indicate 95% CI] PNPLA3 I148M IM/MM vs II unless other specified</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">
<em>p</em>
</th>
</tr></thead>
<tbody valign="top">
<tr><td align="left" colspan="5" valign="top" rowspan="1">Small molecules</td></tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Sundbaum et al. 2021 [<a href="#liv70287-bib-0021" class="usa-link" aria-describedby="liv70287-bib-0021">21</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">Methotrexate</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Primary: ALT &gt; 1.5‐fold upper limit of normal (ULN)</p>
<p>Secondary: peak ALT within 6 months</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Primary: odds ratio (OR) = 0.3147 [0.08745–1.132]</p>
<p>Secondary: beta estimate = −0.08791 [−0.2650–0.08913]</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>
<em>p</em> = 0.0768</p>
<p>
<em>p</em> = 0.33170</p>
</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Guzman et al. 2018 (GLDI) [<a href="#liv70287-bib-0022" class="usa-link" aria-describedby="liv70287-bib-0022">22</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">Adomeglivant (LY2409021)</td>
<td align="center" valign="top" rowspan="1" colspan="1">ALT elevation, expressed as change from baseline (CFB) in IU/L</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>No CFB in placebo group for any PNPLA3 I148M genotype.</p>
<p>CFB in treatment group higher in PNPLA3 I148M carriers than non‐carriers (linear regression model).</p>
<p>PNPLA3 I148M explains 4.22% (<em>R</em>
<sup>2</sup>%) of variance in ALT CFB in the treatment group compared to 0.2% in the placebo group.</p>
<p>Mean CFB (SE) interpreted from Figure <a href="#liv70287-fig-0001" class="usa-link">1A</a>: II ≈7.4 (2.1), IM ≈14.7 (2.3), MM ≈14 (2.6) IU/L</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>
<em>p</em> = 0.83</p>
<p>
<em>p</em> = 0.005</p>
</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Guzman et al. 2018 (GLDJ) [<a href="#liv70287-bib-0022" class="usa-link" aria-describedby="liv70287-bib-0022">22</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Adomeglivant (LY2409021)</p>
<p>Active comparator (AC): sitagliptin</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">ALT elevation, expressed as CFB in IU/L</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>ALT CFB:</p>
<p>No difference in CFB between PNPLA3 I148M genotypes in placebo and active comparator groups.</p>
<p>CFB in treatment group higher in PNPLA3 I148M carriers than non‐carriers (linear regression model)</p>
<p>PNPLA3 I148M explains 7.29% (<em>R</em>
<sup>2</sup>%) of variance in ALT CFB in the LY2409021 group compared to 5.79% and 0.44% in the placebo and active comparator groups.</p>
<p>Mean CFB (SE) interpreted from Figure <a href="#liv70287-fig-0001" class="usa-link">1B</a>: II ≈4.3 (2.7), IM ≈13.2 (3.5), MM ≈31.8 (10) IU/L</p>
<p>Liver fat content (LFC) % (magnetic resonance imaging), CFB [95% CI], II/IM/MM:</p>
<p>Treatment = 3.2 [1.2–5.1]/4.6 [2.2–7.1]/8.6 [1.5–15.7]</p>
<p>AC = −1.2 [−4.2–1.8]/1.7 [−1.2–4.6]/0.4 [−4.7–5.4]</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>
<em>p</em> = 0.45 and 0.61, resp.</p>
<p>
<em>p</em> = 0.059<a href="#liv70287-note-0006" class="usa-link"><sup>*</sup></a>
</p>
<p>
<em>p</em> = 0.27</p>
<p>
<em>p</em> = 0.40</p>
</td>
</tr>
<tr><td align="left" colspan="5" valign="top" rowspan="1">Biologicals</td></tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Capone et al. 2020 [<a href="#liv70287-bib-0023" class="usa-link" aria-describedby="liv70287-bib-0023">23</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">Interferon beta 1 alpha</td>
<td align="center" valign="top" rowspan="1" colspan="1">ALT and/or AST &gt; ULN, graded using the common terminology criteria for adverse events (CTCAE) version 4.0</td>
<td align="center" valign="top" rowspan="1" colspan="1">OR (dominant model) = 2.82 [1.08–7.83]</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<em>p</em> &lt; 0.05</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Feagins et al. 2015 [<a href="#liv70287-bib-0024" class="usa-link" aria-describedby="liv70287-bib-0024">24</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">Tumour necrosis factor alpha inhibitors</td>
<td align="center" valign="top" rowspan="1" colspan="1">ALT &gt; ULN</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Mean peak ALT cases = 111 IU/L (range 69–180)</p>
<p>Mean peak AST cases = 63 IU/L (range 38–88)</p>
<p>75% of cases had PNPLA3 I148M mutations compared to 38% of inflammatory controls.</p>
<p>Mean peak bilirubin cases = 0.98 mg/dL (range 0.6–1.6)</p>
<p>Mean peak alkaline phosphatase cases = 110 IU/L (range 76–172)</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<em>p</em> = 0.31</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Pillai et al. 2018 (IMAGINE‐2) [<a href="#liv70287-bib-0025" class="usa-link" aria-describedby="liv70287-bib-0025">25</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Basal insulin peglispro (LY2605541)</p>
<p>AC: insulin glargine</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">ALT and/or AST elevation, expressed as CFB in IU/L</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>At 26 weeks, ALT CFB (SE), II/IM/MM:</p>
<p>Treatment = 1.92 (0.6)/2.77 (0.72)/1.37 (1.40)</p>
<p>AC = −3.12 (0.82)/−3.47 (0.98)/−0.15 (1.86)</p>
<p>At 26 weeks, AST CFB (SE), II/IM/MM:</p>
<p>Treatment = 1.62 (0.42)/1.83 (0.51)/0.98 (0.97)</p>
<p>AC = −0.84 (0.57)/−1.43 (0.69)/1.46 (1.30)</p>
<p>At 52 weeks, ALT CFB (SE), II/IM/MM:</p>
<p>Treatment = 2.46 (0.61)/6.31 (0.73)/4.74 (1.43)</p>
<p>AC = −2.76 (0.84)/−2.89 (1.01)/2.76 (1.89)</p>
<p>At 52 weeks, AST CFB (SE), II/IM/MM:</p>
<p>Treatment = 2.50 (0.42)/4.33 (0.51)/3.14 (1.00)</p>
<p>AC = −0.70 (0.59)/−0.95 (0.71)/3.55 (1.33)</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>
<em>p</em> = 0.555</p>
<p>
<em>p</em> = 0.277</p>
<p>
<em>p</em> = 0.740</p>
<p>
<em>p</em> = 0.145</p>
<p>
<em>p</em> = 0.0002</p>
<p>
<em>p</em> = 0.021</p>
<p>
<em>p</em> = 0.023</p>
<p>
<em>p</em> = 0.008</p>
</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Pillai et al. 2018 (IMAGINE‐4) [<a href="#liv70287-bib-0025" class="usa-link" aria-describedby="liv70287-bib-0025">25</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Basal insulin peglispro (LY2605541)</p>
<p>AC: insulin glargine</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">ALT and/or AST elevation, expressed as CFB in IU/L</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>ALT CFB (SE), II/IM/MM:</p>
<p>Treatment = 7.08 (0.79)/5.46 (0.94)/13.78 (1.87)</p>
<p>AC = −0.61 (0.78)/−0.52 (0.93)/−4.19 (1.92)</p>
<p>AST CFB (SE), II/IM/MM:</p>
<p>Treatment = 3.65 (0.62)/3.43 (0.73)/11.02 (1.46)</p>
<p>AC = 0.11 (0.61)/−0.31 (0.72)/−1.82 (1.49)</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>
<em>p</em> = 0.0004</p>
<p>
<em>p</em> = 0.197</p>
<p>
<em>p</em> = 7.64 × 10<sup>−6</sup>
</p>
<p>
<em>p</em> = 0.482</p>
</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Pillai et al. 2018 (IMAGINE‐5) [<a href="#liv70287-bib-0025" class="usa-link" aria-describedby="liv70287-bib-0025">25</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Basal insulin peglispro (LY2605541)</p>
<p>AC: insulin glargine</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">ALT and/or AST elevation, expressed as CFB in IU/L</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>At 26 weeks, ALT CFB (SE), II/IM/MM:</p>
<p>Treatment = 7.55 (1.14)/13.90 (1.47)/15.36 (3.45)</p>
<p>AC = 0.96 (1.64)/0.56 (2.07)/−1.27 (3.90)</p>
<p>At 26 weeks, AST CFB (SE), II/IM/MM:</p>
<p>Treatment = 3.49 (0.79)/8.46 (1.02)/10.18 (2.42)</p>
<p>AC = 0.40 (1.14)/0.29 (1.44)/−1.85 (2.70)</p>
<p>At 52 weeks, ALT CFB (SE), II/IM/MM:</p>
<p>Treatment = 6.78 (1.10)/12.33 (1.41)/8.67 (3.29)</p>
<p>AC = −0.05 (1.57)/0.18 (2.02)/−1.29 (3.67)</p>
<p>At 52 weeks, AST CFB (SE), II/IM/MM:</p>
<p>Treatment = 3.32 (0.79)/7.15 (1.01)/5.45 (2.36)</p>
<p>AC = 0.07 (1.13)/−0.95 (0.71)/3.55 (1.33)</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>
<em>p</em> = 0.001</p>
<p>
<em>p</em> = 0.872</p>
<p>
<em>p</em> = 0.00019</p>
<p>
<em>p</em> = 0.956</p>
<p>
<em>p</em> = 0.009</p>
<p>
<em>p</em> = 0.939</p>
<p>
<em>p</em> = 0.012</p>
<p>
<em>p</em> = 0.655</p>
</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Pillai et al. 2018 (pooled) [<a href="#liv70287-bib-0025" class="usa-link" aria-describedby="liv70287-bib-0025">25</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Basal insulin peglispro (LY2605541)</p>
<p>AC: insulin glargine</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">ALT and/or AST elevation, expressed as CFB in IU/L</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>ALT CFB (SE), II/IM/MM:</p>
<p>Treatment = 5.27 (0.46)/6.05 (0.56)/8.60 (1.11)</p>
<p>AC = −0.88 (0.56)/−1.07 (0.66)/−1.96 (1.30)</p>
<p>AST CFB (SE), II/IM/MM:</p>
<p>Treatment = 2.89 (0.34)/3.72 (0.41)/6.36 (0.82)</p>
<p>AC = 0.11 (0.41)/−0.48 (0.49)/−0.48 (0.95)</p>
<p>LFC CFB (SE), II/IM/MM:</p>
<p>Treatment = 1.26 (0.47)/2.6 (0.54)/4.24 (1.27)</p>
<p>AC = −2.82 (0.65)/−1.19 (0.82)/−5.2 (1.74)</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>
<em>p</em> = 0.019</p>
<p>
<em>p</em> = 0.742</p>
<p>
<em>p</em> = 0.0004</p>
<p>
<em>p</em> = 0.599</p>
<p>
<em>p</em> = 0.009</p>
<p>
<em>p</em> = 0.974</p>
</td>
</tr>
<tr><td align="left" colspan="5" valign="top" rowspan="1">Combinatory chemotherapy protocols</td></tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Gutierrez‐Camino et al. 2017 [<a href="#liv70287-bib-0026" class="usa-link" aria-describedby="liv70287-bib-0026">26</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">LAL/SHOP94/99/2005 protocols (induction)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Grade ≥ 2 elevation in ALT and/or AST, graded by the Spanish Society of Paediatric Haematology and Oncology standards</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Hepatotoxicity (grade ≥ 2) OR = 2.06 [0.99–4.29] (dominant model)</p>
<p>High hepatotoxicity (grade ≥ 3) OR = 2.69 [1.09–6.64] (dominant model)</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>
<em>p</em> = 0.051</p>
<p>
<em>p</em> = 0.029</p>
</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Liu et al. 2017 (TOTXV + TOTXVI) [<a href="#liv70287-bib-0027" class="usa-link" aria-describedby="liv70287-bib-0027">27</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">TOTXV or TOTXVI protocols (induction)</td>
<td align="center" valign="top" rowspan="1" colspan="1">ALT elevation, graded using CTCAE version 3.0</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Median increase of 10 IU/L per minor allele (TOTXV)</p>
<p>Median increase of 15 IU/L per minor allele (TOTXVI)</p>
<p>Median increase of 12 IU/L per minor allele (TOTXV + TOTXVI)</p>
<p>Elevation grade ≥ 2, exponent beta coefficient = 1.29 [1.18–1.40] (linear regression)</p>
<p>PNPLA3 I148M explains 3.8% (<em>R</em>
<sup>2</sup>%) of variance in ALT elevation</p>
<p>PNPLA3 I148M remains significant risk factor for postinduction ALT elevation after including diagnostic ALT as covariate</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>
<em>p</em> = 5.5 × 10<sup>−6</sup>
</p>
<p>
<em>p</em> = 2.7 × 10<sup>−4</sup>
</p>
<p>
<em>p</em> = 0.032</p>
<p>
<em>p</em> = 1.2 × 10<sup>−8</sup>
</p>
<p>
<em>p</em> = 4.4 × 10<sup>−6</sup>
</p>
</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Liu et al. 2017 (AALL0232) [<a href="#liv70287-bib-0027" class="usa-link" aria-describedby="liv70287-bib-0027">27</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">COG AALL0232 protocols (induction)</td>
<td align="center" valign="top" rowspan="1" colspan="1">ALT elevation, graded using CTCAE version 4.0</td>
<td align="center" valign="top" rowspan="1" colspan="1">Association between PNPLA3 I148M and frequency of grade &gt; 2 elevations</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<em>p</em> = 0.024</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yang et al. 2022 (AALL0232) [<a href="#liv70287-bib-0028" class="usa-link" aria-describedby="liv70287-bib-0028">28</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">AALL0232 protocols (all treatment phases)</td>
<td align="center" rowspan="2" valign="top" colspan="1">
<p>Grade ≥ 3 ALT and/or AST elevation, graded using CTCAE version 4.0</p>
<p>Grade ≥ 3 hyperbilirubinemia, graded using CTCAE version 4.0</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Association between PNPLA3 I148M and grade ≥ 3 elevations ORs:</p>
<p>Transaminases:</p>
<p>AALL0232 + AALL0434 = 1.27 [1.15–1.40]</p>
<p>AALL0232 = 1.26 [1.12–1.41]</p>
<p>Hyperbilirubinemia:</p>
<p>AALL0232 = 1.43 (95% CI not defined)</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>
<em>p</em> &lt; 0.002</p>
<p>
<em>p</em> = 0.0001</p>
<p>
<em>p</em> = 4.28 × 10<sup>−4</sup>
</p>
</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yang et al. 2022 (AALL0434) [<a href="#liv70287-bib-0028" class="usa-link" aria-describedby="liv70287-bib-0028">28</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">AALL0434 protocols (all treatment phases)</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Association between PNPLA3 I148M and grade ≥ 3 elevations ORs:</p>
<p>Transaminases:</p>
<p>AALL0434 = 1.29 [1.07–1.55]</p>
<p>Hyperbilirubinemia:</p>
<p>AALL0434 = 1.05 (95% CI not defined)</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>
<em>p</em> = 0.007</p>
<p>
<em>p</em> = 0.76</p>
</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/liv70287-tbl-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="liv70287-note-0005"><p>Abbreviations: AC, active comparator; ALT, alanine transaminase; AST, aspartate transaminase; CFB, change from baseline; CTCAE, common terminology criteria for adverse events; LFC, liver fat content; OR, odds ratio; SE, standard error; ULN, upper limit of normal.</p></div>
<div class="fn" id="liv70287-note-0006">
<sup>*</sup><p class="display-inline">Adjusted <em>p</em> &lt; 0.10 was considered significant.</p>
</div>
</div></section><p>The report by Guzman et al. [<a href="#liv70287-bib-0022" class="usa-link" aria-describedby="liv70287-bib-0022">22</a>] covered two separate studies concerning treatment with the glucagon receptor antagonist adomeglivant (LY2409021) in patients with T2DM. The first study was a 6‐week randomised cross‐over study in which 246 patients received either placebo or adomeglivant, alongside diet and exercise alone or in combination with a stable dose of metformin. While no difference in ALT CFB was found based on PNPLA3 I148M genotype during the placebo treatment, the CFB in the treatment arm was significantly higher in patients carrying the PNPLA3 I148M variant (<em>p</em> = 0.005). PNPLA3 I148M explained 4.22% of variance in ALT CFB in the adomeglivant arm compared to 0.2% in the placebo arm. While no numerical values were reported, the mean CFB interpreted from Figure <a href="#liv70287-fig-0001" class="usa-link">1A</a> in the article was around 7.4, 14.7 and 14 IU/L for II, IM and MM genotypes, respectively [<a href="#liv70287-bib-0022" class="usa-link" aria-describedby="liv70287-bib-0022">22</a>]. The second study was a randomised placebo and active comparator‐controlled trial in which 158 T2DM patients on a stable dose of metformin and a sulfonylurea received either placebo, active comparator (sitagliptin) or adomeglivant. Similar to the first study, no difference in CFB based on PNPLA3 I148M was found for the placebo and sitagliptin group, whereas in the adomeglivant group, ALT CFB was increased in carriers of the PNPLA3 I148M variant (<em>p</em> = 0.059, <em>p</em> &lt; 0.1 was considered significant). In this study, PNPLA3 I148M explained 7.29% of variance in the adomeglivant group compared to 5.79% and 0.44% in the sitagliptin and placebo groups, respectively. The mean CFB interpreted from Figure <a href="#liv70287-fig-0001" class="usa-link">1B</a> was around 4.3, 13.2 and 31.8 IU/L for II, IM and MM genotypes, respectively [<a href="#liv70287-bib-0022" class="usa-link" aria-describedby="liv70287-bib-0022">22</a>] (Table <a href="#liv70287-tbl-0002" class="usa-link">2</a>). Taken together, these two studies support the hypothesis that the PNPLA3 I148M variant potentiates ALT elevations upon treatment with adomeglivant.</p>
<figure class="fig xbox font-sm" id="liv70287-fig-0001"><h5 class="obj_head">FIGURE 1.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b05f/12375943/be6e33b94143/LIV-45-0-g002.jpg" loading="lazy" id="jats-graphic-1" height="349" width="709" alt="FIGURE 1"></p>
<div class="p text-right font-secondary"><a href="figure/liv70287-fig-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>
<strong>Narrative synthesis of results.</strong> Some evidence suggests that carriage of a PNPLA3 I148M minor allele confers susceptibility to develop more pronounced aminotransferase elevations in response to drugs, although not all studies accounted for baseline transaminase levels. Based on the criteria of Hy's law, there is no evidence that PNPLA3 I148M increases the propensity to develop clinically relevant hepatocellular drug‐induced liver injury, although it might occur more frequently in paediatric patients carrying PNPLA3 I148M following treatment with chemotherapy protocols. I and M represent a major or minor allele, respectively. PNPLA3, Patatin‐like phospholipase domain‐containing protein 3.</p></figcaption></figure></section><section id="liv70287-sec-0029"><h4 class="pmc_sec_title">3.4.2. Biological Agents</h4>
<p>The five studies employing biological agents covered varying diseases and therapeutic classes. Feagins et al. [<a href="#liv70287-bib-0024" class="usa-link" aria-describedby="liv70287-bib-0024">24</a>] conducted a case–control study in patients with inflammatory diseases receiving treatment with tumour necrosis factor alpha inhibitors (Table <a href="#liv70287-supitem-0001" class="usa-link">S3</a>). They reported that the PNPLA3 I148M minor allele was more frequent in patients who developed transaminase elevations exceeding the ULN compared to matched controls (75% of cases compared to 38% of inflammatory controls, <em>p</em> = 0.31). However, the study included only eight cases, all male and the magnitudes of transaminase elevations were not ascertained, questioning the relevance of these results.</p>
<p>Capone et al. [<a href="#liv70287-bib-0023" class="usa-link" aria-describedby="liv70287-bib-0023">23</a>] investigated the effect of PNPLA3 I148M on transaminase elevations exceeding the ULN upon treatment with interferon beta 1 alpha (IFNβ‐1α) for multiple sclerosis. In their retrospective cohort study covering 113 patients, they found that carriage of the PNPLA3 I148M variant (IM/MM) increased the risk of such elevations (OR = 2.82 [1.08–7.83], <em>p</em> &lt; 0.05).</p>
<p>In the report by Pillai et al. [<a href="#liv70287-bib-0025" class="usa-link" aria-describedby="liv70287-bib-0025">25</a>], the association between PNPLA3 I148M and CFB in ALT and/or AST after treatment with basal insulin peglispro (LY2605541) was investigated in three randomised active comparator‐controlled studies, IMAGINE‐2, IMAGINE‐4 and IMAGINE‐5, and a pooled analysis was also conducted. In IMAGINE‐2, 1364 insulin naïve T2DM patients who were on at least two stable‐dose oral antihyperglycaemic medications received treatment with either peglispro or active comparator insulin glargine. While no statistically significant effect of PNPLA3 I148M was found at the interim analysis after 26 weeks, both ALT and AST mean CFB were significantly higher in carriers of the variant after 52 weeks of treatment with peglispro (II/IM/MM, ALT: 2.46, 6.31, 4.74 IU/L, <em>p</em> &lt; 0.001; AST: 2.50, 4.33, 3.14 IU/L, <em>p</em> = 0.023). A similar effect was found in the active comparator group although in that case, specifically homozygous carriage of PNPLA3 I148M predisposed patients to increased ALT and AST CFB (II/IM/MM, ALT: −2.76, −2.89, 2.76 IU/L, <em>p</em> = 0.021; AST: −0.70, −0.95, 3.55 IU/L, <em>p</em> = 0.008). In the IMAGINE‐4 trial, 1284 T2DM patients on insulin lispro were treated with either peglispro or active comparator insulin glargine for 26 weeks. Significantly increased ALT and AST mean CFB values were found in carriers of the PNPLA3 I148M variant after treatment with peglispro (II/IM/MM, ALT: 7.08, 5.46, 13.78 IU/L, <em>p</em> &lt; 0.001; AST: 3.65, 3.43, 11.02, <em>p</em> &lt; 0.001) but not in the active comparator group. This effect seemed most pronounced in homozygous carriers of the variant allele. In both aforementioned studies, PNPLA3 I148M carriage was also associated with increased ALT and AST at baseline (IMAGINE‐2, <em>p</em> = 0.007 for both and IMAGINE‐4, <em>p</em> &lt; 0.001 and <em>p</em> = 3.75 × 10<sup>−3</sup> respectively). In the IMAGINE‐5 trial, 428 T2DM patients who were already on insulin, or with up to three stable‐dose oral antihyperglycaemic medications, were switched to either peglispro or glargine for 52 weeks. At the interim analysis after 26 weeks, mean ALT and AST CFB were significantly increased in the peglispro group (II/IM/MM, ALT: 7.55, 13.90, 15.36 IU/L, <em>p</em> = 0.001; AST: 3.49, 8.46, 10.18 IU/L, <em>p</em> &lt; 0.001) but not the glargine group. After 52 weeks, these effects persisted (II/IM/MM ALT: 6.78, 12.33, 8.67 IU/L, <em>p</em> = 0.009; AST: 3.32, 7.15, 5.45 IU/L, <em>p</em> = 0.019). The pooled analysis of all three aforementioned studies further emphasised the association between PNPLA3 I148M and increases in CFB of both ALT and AST after 26 weeks of treatment (II/IM/MM, ALT: 5.27, 6.05, 8.60 IU/L, <em>p</em> = 0.019, AST: 2.89, 3.72, 6.36 IU/L, <em>p</em> &lt; 0.001) (Table <a href="#liv70287-tbl-0002" class="usa-link">2</a>). Taken together, these studies provide some evidence for a link between PNPLA3 I148M and moderate serum transaminase elevations after treatment with basal insulin peglispro in T2DM patients.</p></section><section id="liv70287-sec-0030"><h4 class="pmc_sec_title">3.4.3. Combinatory Chemotherapy Protocols</h4>
<p>Five studies investigating chemotherapeutic treatment protocols for children with ALL (Table <a href="#liv70287-supitem-0001" class="usa-link">S3</a>) were included. A retrospective study by Gutierrez‐Camino et al. [<a href="#liv70287-bib-0026" class="usa-link" aria-describedby="liv70287-bib-0026">26</a>] reported an association between carriage of PNPLA3 I148M and the occurrence of ALT and/or AST elevations &gt; 5.1‐fold the ULN during the induction phase of treatment for B‐cell lineage ALL with LAL/SHOP94/99/2005 protocols in a Spanish cohort of 138 children (OR = 2.69 [1.09–6.64], <em>p</em> = 0.029). However, this study appeared to be bias‐prone (Table <a href="#liv70287-supitem-0001" class="usa-link">S5</a>).</p>
<p>The report by Liu et al. [<a href="#liv70287-bib-0027" class="usa-link" aria-describedby="liv70287-bib-0027">27</a>] included 715 patients in a discovery cohort and 2285 patients in a replication cohort. The authors investigated the impact of PNPLA3 I148M on ALT levels during the induction phase of treatment (Table <a href="#liv70287-supitem-0001" class="usa-link">S3</a>). Median increases in ALT per PNPLA3 I148M minor allele of 10 and 15 IU/L were reported for TOTXV and TOTXVI, respectively (<em>p</em> &lt; 0.001 for both), resulting in a pooled median increase of 12 IU/L per allele (<em>p</em> = 0.032). Linear regression analysis further showed an association between PNPLA3 I148M and ALT increases during the induction phase (exponent beta = 1.29 [1.18–1.40], <em>p</em> &lt; 0.001). In this study, PNPLA3 I148M explained 3.8% of variance in postinduction ALT elevations, and PNPLA3 I148M remained a significant risk factor for postinduction ALT elevations when baseline ALT was included as a covariate (<em>p</em> &lt; 0.001). Analysis in the replication cohort confirmed these findings, showing an association between PNPLA3 I148M and the occurrence of ALT elevations &gt; 5‐fold the ULN (<em>p</em> = 0.024), yet no baseline ALT levels were reported, and therefore this result might be biased (Table <a href="#liv70287-tbl-0002" class="usa-link">2</a>).</p>
<p>The report by Yang et al. [<a href="#liv70287-bib-0028" class="usa-link" aria-describedby="liv70287-bib-0028">28</a>] included similar studies, but in this case, the entire duration of treatment was considered. The first study, AALL0232, involved 2283 children receiving treatment for B‐cell lineage ALL, while the second study, AALL0434, included 1274 children being treated for T‐cell lineage ALL (Table <a href="#liv70287-supitem-0001" class="usa-link">S3</a>). An association between PNPLA3 I148M and ALT and/or AST elevations &gt; 5‐fold the ULN was observed in both the AALL0232 study (OR = 1.26 [1.12–1.41], <em>p</em> &lt; 0.001) and AALL0434 study (OR = 1.29 [1.07–1.55], <em>p</em> = 0.007), and in a pooled analysis (OR = 1.27 [1.15–1.40], <em>p</em> &lt; 0.002). No interaction with treatment phase was found for this effect (<em>p</em> = 0.78) (Table <a href="#liv70287-tbl-0002" class="usa-link">2</a>). However, it should be noted that baseline ALT and AST levels were not available in these studies.</p>
<p>Altogether, these studies provide moderate evidence that the PNPLA3 I148M variant may enhance transaminase elevations in paediatric patients upon treatment with chemotherapeutics in the context of ALL.</p></section></section><section id="liv70287-sec-0031"><h3 class="pmc_sec_title">3.5. Results of Syntheses</h3>
<section id="liv70287-sec-0032"><h4 class="pmc_sec_title">3.5.1. Narrative Synthesis</h4>
<p>Results of the narrative synthesis are visually summarised in Figure <a href="#liv70287-fig-0001" class="usa-link">1</a>. Moderate evidence suggests that the PNPLA3 I148M variant potentiates elevations in serum aminotransferases following treatment with biological agents for inflammatory and metabolic diseases, chemotherapeutic protocols in the context of ALL, and treatment with the small molecule adomeglivant for T2DM. There is low to no evidence that individuals who are homozygous for the PNPLA3 major allele (II) may be at increased risk of ALT elevations after treatment with methotrexate.</p>
<p>Some paediatric studies reported on a higher hepatocellular DILI risk in children with PNPLA3 I148M following ALL treatment (ALT and/or AST ≥ 3‐fold ULN), but none of the included studies could show a definite effect of PNPLA3 I148M on clinically relevant hepatocellular DILI because of lacking baseline transaminase levels and individual‐level total bilirubin and ALP levels.</p></section><section id="liv70287-sec-0033"><h4 class="pmc_sec_title">3.5.2. Meta‐Analysis</h4>
<p>All studies included in the meta‐analysis encompassed patients with metabolic impairment, as the study population in all studies consisted of patients with T2DM. Further, all patients were on treatment with diet and exercise or at least one anti‐diabetic medication at a stable dose (i.e., metformin, sulfonylurea and/or insulin) prior to study initiation (Table <a href="#liv70287-supitem-0001" class="usa-link">S3</a>). For three of these studies, LFC measurements by magnetic resonance imaging within each PNPLA3 I148M genetic subgroup were available; these data suggest that overall these patient populations exhibited hepatic steatosis at baseline (LFC around 10%) without significant differences between the IM/MM and II groups (13.7% vs. 12.3%, Table <a href="#liv70287-supitem-0001" class="usa-link">S4</a>).</p>
<p>A random effects model suggested that individuals carrying PNPLA3 IM/MM genotypes may develop higher serum aminotransferase levels after treatment with the small molecule adomeglivant and the biological basal insulin peglispro, both agents that are known to influence lipid metabolism, compared to PNPLA3 II homozygotes (OR = 1.53 [1.22–1.92], <em>p</em> = 0.0002) (Figure <a href="#liv70287-fig-0002" class="usa-link">2</a>). Moderate heterogeneity was present between the studies (τ<sup>2</sup> = 0.0295 [0.0000–0.8722]; <em>I</em>
<sup>2</sup> = 46.5% [0.0–80.4]; and <em>Q</em> = 7.48, <em>p</em> = 0.1127). Asymmetry of the contour‐enhanced funnel plot (Figure <a href="#liv70287-supitem-0001" class="usa-link">S2</a>) suggested that publication bias might be present, which was supported by the addition of two studies by the trim‐and‐fill method to achieve symmetry. However, the impact hereof was limited as the adjusted trim‐and‐fill random effects estimate did not deviate from the original result (OR = 1.39 [1.12–1.72], <em>p</em> = 0.0024). Meta‐regression did not reveal significant contributions from differences between PNPLA3 IM/MM and II subgroups in baseline factors such as age, sex, duration of T2DM, BMI, serum triglycerides, %Hb1Ac and transaminase levels. Moreover, in the subgroup for which LFC measurements and CFB in LFC, triglycerides and %Hb1Ac were available in both PNPLA3 genetic subgroups, inclusion of these covariates did not significantly change the outcome of the meta‐analysis (Table <a href="#liv70287-supitem-0001" class="usa-link">S8</a>).</p>
<figure class="fig xbox font-sm" id="liv70287-fig-0002"><h5 class="obj_head">FIGURE 2.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b05f/12375943/af02688bb563/LIV-45-0-g001.jpg" loading="lazy" id="jats-graphic-3" height="345" width="709" alt="FIGURE 2"></p>
<div class="p text-right font-secondary"><a href="figure/liv70287-fig-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Forest plot of the meta‐analysis. The included records covered studies investigating the effect of adomeglivant (a glucagon receptor antagonist) and basal insulin peglispro in patients with type 2 diabetes mellitus. I and M represent a major or minor allele, respectively. Symbol sizes are proportional to the weight of the studies in the meta‐analysis, determined by the width of their 95% confidence intervals. CI, confidence interval; OR, odds ratio; SE, standard error.</p></figcaption></figure></section></section><section id="liv70287-sec-0034"><h3 class="pmc_sec_title">3.6. Reporting Biases</h3>
<p>Four studies did not mention registration of the study protocol. Only one registered study protocol included the investigation of pharmacogenetic predictors for treatment‐related outcomes; however, it did not specify the investigation of PNPLA3 I148M (Table <a href="#liv70287-supitem-0001" class="usa-link">S9</a>). Altogether, these factors may have contributed to selective reporting and publication bias.</p></section></section><section id="liv70287-sec-0035"><h2 class="pmc_sec_title">4. Discussion</h2>
<p>DILI is a major cause of acute liver injury [<a href="#liv70287-bib-0003" class="usa-link" aria-describedby="liv70287-bib-0003">3</a>, <a href="#liv70287-bib-0004" class="usa-link" aria-describedby="liv70287-bib-0004">4</a>], but the contributing host factors are poorly defined. In this systematic review with meta‐analysis, we found no definite effect of PNPLA3 I148M on the occurrence of clinically relevant DILI, although the meta‐analysis suggested that carriage of the variant could confer susceptibility to develop increased serum transaminases in response to drugs that influence lipid metabolism (i.e., adomeglivant and basal insulin peglispro in the context of T2DM). Similar results were seen in a study from the USA DILI Network, where no association between PNPLA3 I148M and the risk of development, severity, or outcome of DILI caused by 177 agents in a cohort of 832 cases and 10 397 controls was seen, although the authors noted that the variant could still be involved in DILI related to specific drugs [<a href="#liv70287-bib-0030" class="usa-link" aria-describedby="liv70287-bib-0030">30</a>]. In this context, a phenome‐wide association study suggested that carriage of PNPLA3 I148M may be associated with aspirin‐ and ibuprofen‐, but not naproxen‐related DILI [<a href="#liv70287-bib-0031" class="usa-link" aria-describedby="liv70287-bib-0031">31</a>]. Because these findings were only supported by data from one out of four included cohorts, which relied on questionnaire‐based self‐reports as a source for the phenotypes, further investigation and independent replication are needed.</p>
<p>The underlying mechanisms that could explain the findings of the present study are unclear but likely lie in the context of lipid metabolism. The PNPLA3 I148M variant has been linked to elevated transaminase levels in both adults and children [<a href="#liv70287-bib-0010" class="usa-link" aria-describedby="liv70287-bib-0010">10</a>, <a href="#liv70287-bib-0032" class="usa-link" aria-describedby="liv70287-bib-0032">32</a>], and treatments causing or contributing to hepatic lipid accumulation may hence amplify this effect. In this context, insulin is known to promote hepatic de novo lipogenesis and hyperinsulinemia, which occurs in insulin‐resistant individuals, can result in hepatic steatosis [<a href="#liv70287-bib-0033" class="usa-link" aria-describedby="liv70287-bib-0033">33</a>]. In patients with insulin resistance, the PNPLA3 I148M variant has also been linked to reduced circulating very low‐density lipoprotein (VLDL) particles that are smaller in size compared to those found in non‐carriers of the variant [<a href="#liv70287-bib-0034" class="usa-link" aria-describedby="liv70287-bib-0034">34</a>]. A recent study suggested that impaired lipidation of VLDL and reduced triglyceride secretion could be key contributors to PNPLA3 I148M‐mediated hepatic steatosis. Under lipogenic stimulation, wild‐type PNPLA3 plays a crucial role in mobilising polyunsaturated fatty acids from the triglyceride pool to synthesise phospholipids, which are in turn used for the synthesis and secretion of large, triglyceride‐rich VLDLs, while this process is impaired for PNPLA3 I148M [<a href="#liv70287-bib-0035" class="usa-link" aria-describedby="liv70287-bib-0035">35</a>].</p>
<p>Data from multiple phase 2 and 3 trials comparing basal insulin peglispro and insulin glargine for treatment of both type 1 and type 2 diabetes suggested that basal insulin peglispro, despite being superior in lowering HbA1c, caused ALT elevations in both study populations which were more often found to be &gt; 3‐fold the ULN when compared to glargine. Moreover, in type 1 diabetes mellitus and T2DM patients previously treated with basal insulin, basal insulin peglispro caused a significant increase in LFC which was not observed in the glargine treatment group. The absence of this effect in the insulin naïve population suggests that withdrawal of basal insulin, and thus loss of suppression of peripheral lipolysis, may have contributed to this effect. A positive correlation was found between increased LFC and increases in ALT and triglycerides, irrespective of the study population [<a href="#liv70287-bib-0036" class="usa-link" aria-describedby="liv70287-bib-0036">36</a>]. Given that the prevalence of MASLD in patients with T2DM is around 65% [<a href="#liv70287-bib-0037" class="usa-link" aria-describedby="liv70287-bib-0037">37</a>], a further study investigated whether carriage of genetic polymorphisms linked to MASLD could further explain these findings. Pillai et al. [<a href="#liv70287-bib-0025" class="usa-link" aria-describedby="liv70287-bib-0025">25</a>] found that a switch from basal insulins, which suppress lipolysis, to hepato‐preferential basal insulin peglispro, resulted in higher serum transaminase elevations in carriers of the PNPLA3 I148M variant. When peripheral lipolysis receives less suppression from insulin, the flux of free fatty acids to the liver increases, resulting in triglyceride re‐esterification, VLDL secretion, and thus increased hepatic lipid turnover. Furthermore, systemic palmitate flux was found to be 35% higher in patients with type 1 diabetes treated with peglispro than those treated with glargine [<a href="#liv70287-bib-0038" class="usa-link" aria-describedby="liv70287-bib-0038">38</a>]. Considering that PNPLA3 I148M impairs VLDL lipidation, and that patients with MASLD who carry the PNPLA3 I148M variant benefit especially from interventions that reduce hepatic fatty acid flux such as lifestyle interventions, loss of peripheral suppression of lipolysis by conventional insulins may have an enhanced impact on hepatic steatosis in these patients [<a href="#liv70287-bib-0015" class="usa-link" aria-describedby="liv70287-bib-0015">15</a>].</p>
<p>Elevation of serum transaminases was a common side‐effect observed in clinical trials investigating glucagon receptor antagonists, and liver injury was one of the key safety concerns resulting in cessation of their clinical development [<a href="#liv70287-bib-0039" class="usa-link" aria-describedby="liv70287-bib-0039">39</a>]. While the exact mechanisms behind this adverse effect remain to be elucidated, a recent study showed that a physiological increase in circulating glucagon stimulates hepatic mitochondrial oxidation in both healthy controls and individuals with liver steatosis, and several (dual) glucagon receptor agonists are currently under investigation in clinical trials for obesity, T2DM and MASLD [<a href="#liv70287-bib-0040" class="usa-link" aria-describedby="liv70287-bib-0040">40</a>, <a href="#liv70287-bib-0041" class="usa-link" aria-describedby="liv70287-bib-0041">41</a>, <a href="#liv70287-bib-0042" class="usa-link" aria-describedby="liv70287-bib-0042">42</a>]. In both a 6‐week and 6‐month trial, the glucagon receptor antagonist adomeglivant caused marked elevations of serum aminotransferases in patients with T2DM and PNPLA3 IM/MM genotypes compared to II carriers. This was not observed in the placebo or active comparator groups and thus suggests that an interaction between adomeglivant and carriage of PNPLA3 I148M may contribute to the observed transaminase elevations. Since the PNPLA3 I148M variant has been linked to hepatic mitochondrial dysfunction and increased mitochondrial stress in humans, further impairment of hepatic mitochondrial function due to blocking glucagon receptor signalling could have been one of the mechanisms that contributed to this effect [<a href="#liv70287-bib-0043" class="usa-link" aria-describedby="liv70287-bib-0043">43</a>].</p>
<p>In the context of cancer treatments, a recent study demonstrated that an interaction between oestrogen receptor alpha and PNPLA3 I148M may contribute to steatotic liver disease susceptibility in women. In vitro data showed that exposure to the selective oestrogen receptor modulator tamoxifen, used for treatment of oestrogen‐sensitive cancers, resulted in upregulation of PNPLA3 mRNA and protein levels, as well as accumulation of PNPLA3 I148M on intracellular lipid droplets in HepG2 cells [<a href="#liv70287-bib-0044" class="usa-link" aria-describedby="liv70287-bib-0044">44</a>]. As tamoxifen intake has been linked to the development of hepatic steatosis in patients [<a href="#liv70287-bib-0045" class="usa-link" aria-describedby="liv70287-bib-0045">45</a>], it is plausible that carriage of the PNPLA3 I148M variant may worsen the development of DILI in such cases. Unfortunately, no studies regarding tamoxifen‐related DILI were found in the context of this systematic review; clinical data is needed to further investigate this possible interaction.</p>
<p>Some evidence was found that carriers of PNPLA3 I148M may develop excess hepatotoxicity in response to combinatory chemotherapy protocols in the paediatric population. Although these data are complex to interpret, it remains valuable to explore a possible effect of PNPLA3 I148M on increased serum transaminase levels in this context, given that individuals receiving these treatments often develop hepatotoxicity. Identifying one specific agent that was responsible for the observed transaminase elevations is unfeasible, and also other factors beyond chemotherapeutics may contribute to it, including hepatic infiltration of ALL and drugs used in supportive care, such as antibiotics [<a href="#liv70287-bib-0028" class="usa-link" aria-describedby="liv70287-bib-0028">28</a>]. The included studies by Lui et al. [<a href="#liv70287-bib-0027" class="usa-link" aria-describedby="liv70287-bib-0027">27</a>] and Gutierrez‐Camino et al. [<a href="#liv70287-bib-0026" class="usa-link" aria-describedby="liv70287-bib-0026">26</a>] reported PNPLA3 I148M as a possible driver to develop elevated serum transaminases after induction therapy with the TOTXV, TOTXVI and LAL/SHOP/94/99/2005 protocols. A cross‐sectional study of 300 paediatric ALL patients receiving induction therapy with UKALL 2003 protocols, including PEGylated asparaginase, vincristine and dexamethasone, confirmed these findings at the organ level by showing a significant association between PNPLA3 I148M and postinduction hepato(spleno)megaly (dominant logistic regression model, OR = 3.79 [2.29–6.28], <em>p</em> adjusted &lt; 0.05) [<a href="#liv70287-bib-0046" class="usa-link" aria-describedby="liv70287-bib-0046">46</a>]. This association was independent of age, sex, ALL lineage, or the addition of daunorubicin to the protocol. The induction regimens of the aforementioned studies all included asparaginase, vincristine and a corticosteroid, with some also including methotrexate, daunorubicin, or cytarabine. Liu et al. found in their discovery cohort that postinduction ALT elevations were associated with the TOTXVI treatment protocol, which uses PEGylated asparaginase (<em>p</em> = 0.025), and additional doses of asparaginase (<em>p</em> &lt; 0.001). Notably, grade 2–3 ALT elevations were more frequently observed in patients treated with the TOTXVI protocol than in those receiving the TOTXV protocol (<em>p</em> = 5.8 × 10<sup>−3</sup>). Moreover, the TOTXV protocol included high‐dose methotrexate, while the TOTXVI protocol did not. These findings somewhat suggest that asparaginase, and particularly the more potent PEGylated form used in the TOTXVI protocol, is the predominant driver of postinduction ALT elevations in this cohort. In mice, rather than having direct hepatotoxic effects, PEGylated asparaginase was found to induce lipolysis in adipose tissue, hereby increasing fatty acid flux to the liver, resulting in steatosis. This activation of lipolysis was confirmed in an in vitro model using differentiated 3T3‐L1 adipocytes, leading to increased non‐esterified fatty acids in the cell culture supernatant [<a href="#liv70287-bib-0047" class="usa-link" aria-describedby="liv70287-bib-0047">47</a>]. It is plausible that the PNPLA3 I148M variant amplifies this indirect mechanism of hepatotoxicity in a similar manner as discussed for basal insulin peglispro, by increasing hepatic retention and reducing VLDL‐mediated secretion of triglycerides. However, the study by Yang et al. [<a href="#liv70287-bib-0028" class="usa-link" aria-describedby="liv70287-bib-0028">28</a>] reported that the effect of PNPLA3 I148M on serum transaminase elevations was unrelated to treatment phase, suggesting that patients with this variant may have an overall increased susceptibility to hepatotoxicity, rather than an interaction with a specific treatment agent.</p>
<p>In line with this, apart from some specific lipid metabolism‐related effects mediated by PNPLA3 I148M, a higher burden of pre‐existing MASLD in the PNPLA3 I148M groups could have made these individuals more prone to develop hepatotoxicity [<a href="#liv70287-bib-0048" class="usa-link" aria-describedby="liv70287-bib-0048">48</a>, <a href="#liv70287-bib-0049" class="usa-link" aria-describedby="liv70287-bib-0049">49</a>]. A large study including 4837 individuals with suspected MASLD and controls investigated the risk of suspected DILI caused by the top 10 medications that most frequently cause DILI. Suspected DILI was defined as ALT &gt; 200 IU/L, alkaline phosphatase &gt; 250 IU/L and/or total bilirubin &gt; 2.5 mg/dL within 3 months of drug prescription at two or more consecutive laboratory tests. Suspected DILI occurred in 0.8% of the group with suspected MASLD, which was significantly higher compared to the controls without MASLD (0.2%), suggesting that MASLD can be a relevant condition predisposing to hepatotoxicity [<a href="#liv70287-bib-0050" class="usa-link" aria-describedby="liv70287-bib-0050">50</a>]. The relation between DILI and PNPLA3 I148M could therefore be bidirectional, with some drugs enhancing liver steatosis and pre‐existing liver disease predisposing to develop DILI [<a href="#liv70287-bib-0051" class="usa-link" aria-describedby="liv70287-bib-0051">51</a>]. Indeed, pre‐existing liver disease can also alter drug pharmacokinetics and MASLD has been specifically linked to clinically important reductions in expression of CYP2C19, which is responsible for the metabolism of many drugs [<a href="#liv70287-bib-0052" class="usa-link" aria-describedby="liv70287-bib-0052">52</a>, <a href="#liv70287-bib-0053" class="usa-link" aria-describedby="liv70287-bib-0053">53</a>]. Thus, although PNPLA3 is not a pharmacogene, it is plausible that the resulting liver‐related effects caused by the I148M variant can indirectly influence pharmacokinetics and DILI potential of drugs [<a href="#liv70287-bib-0053" class="usa-link" aria-describedby="liv70287-bib-0053">53</a>, <a href="#liv70287-bib-0054" class="usa-link" aria-describedby="liv70287-bib-0054">54</a>].</p>
<p>Moreover, several studies have reported a synergistic interaction between PNPLA3 I148M and BMI when it comes to elevated serum ALT and hepatic steatosis [<a href="#liv70287-bib-0055" class="usa-link" aria-describedby="liv70287-bib-0055">55</a>, <a href="#liv70287-bib-0056" class="usa-link" aria-describedby="liv70287-bib-0056">56</a>]. Notably, in both children and adults with steatotic liver disease, BMI above 30 kg/m<sup>2</sup> was found to confer an exponential increase in the relationship between PNPLA3 I148M and risk for advanced fibrosis [<a href="#liv70287-bib-0057" class="usa-link" aria-describedby="liv70287-bib-0057">57</a>]. Whether this interaction also affects the risk for hepatocellular DILI remains unclear. In the meta‐regression, the mean difference between PNPLA3 IM/MM and II in baseline BMI did not significantly affect the odds of enlarged serum aminotransferase elevations (estimate = −0.4026, adjusted <em>p</em> = 0.196), nor did baseline BMI in the PNPLA3 IM/MM group (estimate = −0.0979, adjusted <em>p</em> = 0.211). In a study regarding treatment with basal insulin peglispro in insulin‐naïve patients with T2DM, CFB in LFC was found to correlate negatively with baseline BMI. The same study did report a positive correlation between CFB in LFC and CFB in BMI, irrespective of previous insulin treatment, suggesting that it is not the patients with a high baseline BMI that are at risk but rather the patients who exhibit an increase in this parameter during treatment [<a href="#liv70287-bib-0036" class="usa-link" aria-describedby="liv70287-bib-0036">36</a>]. Unfortunately, CFB BMI data per PNPLA3 I148M genetic subgroup were not available for any of the studies in the meta‐regression. Interestingly, in the GLDJ study, patients with PNPLA3 MM genotype had a lower baseline BMI (II/IM/MM, mean BMI: 32.6, 31.4, 26.9 kg/m, <em>p</em>‐value not declared), yet they exhibited larger elevations in ALT compared to patients with PNPLA3 II and IM genotypes after treatment with adomeglivant (Δ mean CFB MM vs. II ≈28 IU/L, vs. IM ≈20 IU/L) [<a href="#liv70287-bib-0022" class="usa-link" aria-describedby="liv70287-bib-0022">22</a>]. Similarly, carriers of the PNPLA3 I148M variant in the pooled IMAGINE trials exhibited a slightly lower BMI at baseline (II/IM/MM, mean BMI: 32.92, 32.34, 32.38, <em>p</em> = 0.03) yet exhibited a significantly higher CFB in ALT, AST and LFC after treatment with basal insulin peglispro [<a href="#liv70287-bib-0025" class="usa-link" aria-describedby="liv70287-bib-0025">25</a>]. It should be noted that for all studies in the meta‐analysis, the mean BMI was above 30 kg/m<sup>2</sup> in both the PNPLA3 II and PNPLA3 IM/MM groups. Further, Liu et al. reported a positive correlation between postinduction ALT elevations and BMI percentile, which remained significant after adjustment for PNPLA3 I148M carriage (<em>p</em> = 0.0027). Nevertheless, data regarding the interaction between PNPLA3 I148M and either baseline or CFB BMI on drug‐induced serum aminotransferase elevations are scarce, and further investigation is needed.</p>
<p>Our study should be interpreted in the context of its limitations. While elevations in ALT and AST are sensitive signals of hepatocellular injury, especially AST is an unspecific parameter and can be increased because of, for example, cardiac toxicity and muscle damage. In line with this, there was insufficient data to cover all parameters of Hy's law as a more specific measure of potential severe hepatocellular DILI [<a href="#liv70287-bib-0007" class="usa-link" aria-describedby="liv70287-bib-0007">7</a>, <a href="#liv70287-bib-0008" class="usa-link" aria-describedby="liv70287-bib-0008">8</a>], although most studies did not report on severe DILI cases. Second, the included studies were not primarily powered to detect differences between PNPLA3 I148M subgroups and were retrospective in nature, which are sources of bias that could not be controlled for. Third, the relatively small number of studies, along with the heterogeneity of their summary measures, are additional possibly biasing factors, while severe DILI is rare and most compounds had a relatively safe toxicity profile [<a href="#liv70287-bib-0001" class="usa-link" aria-describedby="liv70287-bib-0001">1</a>, <a href="#liv70287-bib-0002" class="usa-link" aria-describedby="liv70287-bib-0002">2</a>]. Last, not all studies ascertained the presence of MASLD or MASH that could have been more prevalent in the people carrying PNPLA3 I148M, which could have conferred an increased risk to develop hepatotoxicity [<a href="#liv70287-bib-0053" class="usa-link" aria-describedby="liv70287-bib-0053">53</a>, <a href="#liv70287-bib-0054" class="usa-link" aria-describedby="liv70287-bib-0054">54</a>].</p></section><section id="liv70287-sec-0036"><h2 class="pmc_sec_title">5. Conclusion</h2>
<p>There is low to no evidence that carriage of PNPLA3 contributes to clinically relevant hepatocellular DILI; although it may amplify drug‐induced transaminase elevations attributed to adomeglivant and basal insulin peglispro, which are both known to influence liver lipid metabolism in individuals with metabolic impairment. A higher prevalence or severity of MASLD may have mediated the observed effect of PNPLA3 I148M on the more pronounced increase of transaminases in response to these drugs.</p></section><section id="liv70287-sec-0037"><h2 class="pmc_sec_title">Author Contributions</h2>
<p>A.G.: conceptualization, formal analysis (lead), investigation, methodology, visualisation, writing – original draft preparation. L.M.: formal analysis (supporting), investigation, methodology, writing – review and editing. H.H.: methodology, writing – review and editing. J.M.S.: methodology, writing – review and editing. R.M.R.: methodology, writing – review and editing. T.V.: methodology, supervision, writing – review and editing. J.B.: conceptualization, formal analysis (supporting), methodology, supervision, writing – review and editing.</p></section><section id="liv70287-sec-0039"><h2 class="pmc_sec_title">Ethics Statement</h2>
<p>The systematic review is registered in the PROSPERO register (CRD42024557488).</p></section><section id="liv70287-sec-0038"><h2 class="pmc_sec_title">Conflicts of Interest</h2>
<p>J.B. reports research funding from Colgate‐Palmolive outside the submitted work. H.H. reports research funding from AstraZeneca, EchoSens, Gilead, Intercept, MSD, Novo Nordisk and Pfizer. He has served as a consultant for AstraZeneca and Novo Nordisk and has been or is part of hepatic events adjudication committees for Arrowhead, Boehringer Ingelheim, KOWA and GW Pharma. J.M.S. reports consulting for Alentis, Alexion, Altimmune, Astra Zeneca, 89Bio, Bionorica, Boehringer Ingelheim, Gilead Sciences, GSK, Ipsen, Inventiva Pharma, Madrigal Pharmaceuticals, Lilly, MSD, Northsea Therapeutics, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi and Siemens Healthineers. speaker honorarium from AbbVie, Academic Medical Education (AME), Boehringer Ingelheim, Echosens, Forum für Medizinische Fortbildung (FOMF), Gilead Sciences, MedicalTribune, MedPublico GmbH, MedScape, Novo Nordisk, Madrigal Pharmaceuticals, Stockholder options: AGED diagnostics and Hepta Bio. The other authors declare no potential conflicts of interest.</p></section><section id="sec38"><h2 class="pmc_sec_title">Supporting information</h2>
<section class="sm xbox font-sm" id="liv70287-supitem-0001"><div class="caption p"><p>
<strong>Appendix S1:</strong> liv70287‐sup‐0001‐AppendixS1.zip.</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12375943/bin/LIV-45-0-s001.zip" data-ga-action="click_feat_suppl" class="usa-link">LIV-45-0-s001.zip</a><sup> (124.7KB, zip) </sup>
</div></div></section></section><section id="notes1"><p>

Gatzios A., Marchandise L., Hagström H., et al., “Impact of PNPLA3 I148M on Drug‐Induced Hepatocellular Liver Injury: A Systematic Review and Meta‐Analysis,” Liver International
45, no. 9 (2025): e70287, 10.1111/liv.70287.

</p>
<section id="liv70287-ntgp-0001" class="fn-group"><div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="liv70287-note-0001"><p>
<strong>Funding:</strong> This work was supported by Fonds Wetenschappelijk Onderzoek, 1S91925N; Chair Mireille Aerens for the Development of Alternative Methods.</p></div>
<div class="fn p" id="liv70287-note-0002"><p>Alexandra Gatzios and Lorna Marchandise are first authors.</p></div>
<div class="fn p" id="liv70287-note-0003"><p>Tamara Vanhaecke and Joost Boeckmans are last authors.</p></div>
<div class="fn p" id="liv70287-note-0101"><p>
<strong>Handling Editor:</strong> Dr. Luca Valenti</p></div>
</div></section></section><section id="liv70287-sec-0041"><h2 class="pmc_sec_title">Data Availability Statement</h2>
<p>Data sharing not applicable to this article as no new data were generated for this study. All data used to perform the meta‐analysis are available within the paper and Appendix <a href="#liv70287-supitem-0001" class="usa-link">S1</a>.</p></section><section id="liv70287-bibl-0001" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="liv70287-bibl-0001_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="liv70287-bib-0001">
<span class="label">1.</span><cite>
Sgro C., Clinard F., Ouazir K., et al., “Incidence of Drug‐Induced Hepatic Injuries: A French Population‐Based Study,” Hepatology
36, no. 2 (2002): 451–455.
</cite> [<a href="https://doi.org/10.1053/jhep.2002.34857" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12143055/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&amp;title=Incidence%20of%20Drug%E2%80%90Induced%20Hepatic%20Injuries:%20A%20French%20Population%E2%80%90Based%20Study&amp;author=C.%20Sgro&amp;author=F.%20Clinard&amp;author=K.%20Ouazir&amp;volume=36&amp;issue=2&amp;publication_year=2002&amp;pages=451-455&amp;pmid=12143055&amp;doi=10.1053/jhep.2002.34857&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0002">
<span class="label">2.</span><cite>
Björnsson E. S., Bergmann O. M., Björnsson H. K., et al., “Incidence, Presentation, and Outcomes in Patients With Drug‐Induced Liver Injury in the General Population of Iceland,” Gastroenterology
144, no. 7 (2013): 1419–1425.
</cite> [<a href="https://doi.org/10.1053/j.gastro.2013.02.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23419359/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&amp;title=Incidence,%20Presentation,%20and%20Outcomes%20in%20Patients%20With%20Drug%E2%80%90Induced%20Liver%20Injury%20in%20the%20General%20Population%20of%20Iceland&amp;author=E.%20S.%20Bj%C3%B6rnsson&amp;author=O.%20M.%20Bergmann&amp;author=H.%20K.%20Bj%C3%B6rnsson&amp;volume=144&amp;issue=7&amp;publication_year=2013&amp;pages=1419-1425&amp;pmid=23419359&amp;doi=10.1053/j.gastro.2013.02.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0003">
<span class="label">3.</span><cite>
Reuben A., Tillman H., Fontana R. J., et al., “Outcomes in Adults With Acute Liver Failure Between 1998 and 2013: An Observational Cohort Study,” Annals of Internal Medicine
164, no. 11 (2016): 724–732.
</cite> [<a href="https://doi.org/10.7326/M15-2211" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5526039/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27043883/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annals%20of%20Internal%20Medicine&amp;title=Outcomes%20in%20Adults%20With%20Acute%20Liver%20Failure%20Between%201998%20and%202013:%20An%20Observational%20Cohort%20Study&amp;author=A.%20Reuben&amp;author=H.%20Tillman&amp;author=R.%20J.%20Fontana&amp;volume=164&amp;issue=11&amp;publication_year=2016&amp;pages=724-732&amp;pmid=27043883&amp;doi=10.7326/M15-2211&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0004">
<span class="label">4.</span><cite>
Lenz D., Hørby Jørgensen M., Kelly D., et al., “Etiology and Outcome of Adult and Pediatric Acute Liver Failure in Europe,” Journal of Pediatric Gastroenterology and Nutrition
77, no. 1 (2023): 115–120.
</cite> [<a href="https://doi.org/10.1097/MPG.0000000000003777" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36930963/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Pediatric%20Gastroenterology%20and%20Nutrition&amp;title=Etiology%20and%20Outcome%20of%20Adult%20and%20Pediatric%20Acute%20Liver%20Failure%20in%20Europe&amp;author=D.%20Lenz&amp;author=M.%20H%C3%B8rby%20J%C3%B8rgensen&amp;author=D.%20Kelly&amp;volume=77&amp;issue=1&amp;publication_year=2023&amp;pages=115-120&amp;pmid=36930963&amp;doi=10.1097/MPG.0000000000003777&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0005">
<span class="label">5.</span><cite>
Germani G., Theocharidou E., Adam R., et al., “Liver Transplantation for Acute Liver Failure in Europe: Outcomes Over 20 Years From the ELTR Database,” Journal of Hepatology
57, no. 2 (2012): 288–296.
</cite> [<a href="https://doi.org/10.1016/j.jhep.2012.03.017" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22521347/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Hepatology&amp;title=Liver%20Transplantation%20for%20Acute%20Liver%20Failure%20in%20Europe:%20Outcomes%20Over%2020%E2%80%89Years%20From%20the%20ELTR%20Database&amp;author=G.%20Germani&amp;author=E.%20Theocharidou&amp;author=R.%20Adam&amp;volume=57&amp;issue=2&amp;publication_year=2012&amp;pages=288-296&amp;pmid=22521347&amp;doi=10.1016/j.jhep.2012.03.017&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0006">
<span class="label">6.</span><cite>
Watkins P. B., “Drug Safety Sciences and the Bottleneck in Drug Development,” Clinical Pharmacology and Therapeutics
89, no. 6 (2011): 788–790.
</cite> [<a href="https://doi.org/10.1038/clpt.2011.63" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21593756/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20Pharmacology%20and%20Therapeutics&amp;title=Drug%20Safety%20Sciences%20and%20the%20Bottleneck%20in%20Drug%20Development&amp;author=P.%20B.%20Watkins&amp;volume=89&amp;issue=6&amp;publication_year=2011&amp;pages=788-790&amp;pmid=21593756&amp;doi=10.1038/clpt.2011.63&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0007">
<span class="label">7.</span><cite>
Andrade R. J., Aithal G. P., and Björnsson E. S., “EASL Clinical Practice Guidelines: Drug‐Induced Liver Injury,” Journal of Hepatology
70, no. 6 (2019): 1222–1261.
</cite> [<a href="https://doi.org/10.1016/j.jhep.2019.02.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30926241/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Hepatology&amp;title=EASL%20Clinical%20Practice%20Guidelines:%20Drug%E2%80%90Induced%20Liver%20Injury&amp;author=R.%20J.%20Andrade&amp;author=G.%20P.%20Aithal&amp;author=E.%20S.%20Bj%C3%B6rnsson&amp;volume=70&amp;issue=6&amp;publication_year=2019&amp;pages=1222-1261&amp;pmid=30926241&amp;doi=10.1016/j.jhep.2019.02.014&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0008">
<span class="label">8.</span><cite>
U.S. Department of Health and Human Services
, Food and Drug Administration
, Center for Drug Evaluation and Research (CDER)
, et al., “Guidance for Industry Drug‐Induced Liver Injury: Premarketing Clinical Evaluation. Drug Safety,” (2009), 1‐28.</cite>
</li>
<li id="liv70287-bib-0009">
<span class="label">9.</span><cite>
Li X., Tang J., and Mao Y., “Incidence and Risk Factors of Drug‐Induced Liver Injury,” Liver International
42, no. 9 (2022): 1999–2014.
</cite> [<a href="https://doi.org/10.1111/liv.15262" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35353431/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Liver%20International&amp;title=Incidence%20and%20Risk%20Factors%20of%20Drug%E2%80%90Induced%20Liver%20Injury&amp;author=X.%20Li&amp;author=J.%20Tang&amp;author=Y.%20Mao&amp;volume=42&amp;issue=9&amp;publication_year=2022&amp;pages=1999-2014&amp;pmid=35353431&amp;doi=10.1111/liv.15262&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0010">
<span class="label">10.</span><cite>
Romeo S., Kozlitina J., Xing C., et al., “Genetic Variation in PNPLA3 Confers Susceptibility to Nonalcoholic Fatty Liver Disease,” Nature Genetics
40, no. 12 (2008): 1461–1465.
</cite> [<a href="https://doi.org/10.1038/ng.257" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2597056/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18820647/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Genetics&amp;title=Genetic%20Variation%20in%20PNPLA3%20Confers%20Susceptibility%20to%20Nonalcoholic%20Fatty%20Liver%20Disease&amp;author=S.%20Romeo&amp;author=J.%20Kozlitina&amp;author=C.%20Xing&amp;volume=40&amp;issue=12&amp;publication_year=2008&amp;pages=1461-1465&amp;pmid=18820647&amp;doi=10.1038/ng.257&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0011">
<span class="label">11.</span><cite>
Dai G., Liu P., Li X., Zhou X., and He S., “Association Between PNPLA3 Rs738409 Polymorphism and Nonalcoholic Fatty Liver Disease (NAFLD) Susceptibility and Severity: A Meta‐Analysis,” Medicine (Baltimore)
98, no. 7 (2019): e14324.
</cite> [<a href="https://doi.org/10.1097/MD.0000000000014324" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6407996/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30762732/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Medicine%20(Baltimore)&amp;title=Association%20Between%20PNPLA3%20Rs738409%20Polymorphism%20and%20Nonalcoholic%20Fatty%20Liver%20Disease%20(NAFLD)%20Susceptibility%20and%20Severity:%20A%20Meta%E2%80%90Analysis&amp;author=G.%20Dai&amp;author=P.%20Liu&amp;author=X.%20Li&amp;author=X.%20Zhou&amp;author=S.%20He&amp;volume=98&amp;issue=7&amp;publication_year=2019&amp;pages=e14324&amp;pmid=30762732&amp;doi=10.1097/MD.0000000000014324&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0012">
<span class="label">12.</span><cite>
Valenti L., Dongiovanni P., Ginanni Corradini S., Burza M. A., and Romeo S., “PNPLA3 I148M Variant and Hepatocellular Carcinoma: A Common Genetic Variant for a Rare Disease,” Digestive and Liver Disease
45, no. 8 (2013): 619–624.
</cite> [<a href="https://doi.org/10.1016/j.dld.2012.12.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23333103/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Digestive%20and%20Liver%20Disease&amp;title=PNPLA3%20I148M%20Variant%20and%20Hepatocellular%20Carcinoma:%20A%20Common%20Genetic%20Variant%20for%20a%20Rare%20Disease&amp;author=L.%20Valenti&amp;author=P.%20Dongiovanni&amp;author=S.%20Ginanni%20Corradini&amp;author=M.%20A.%20Burza&amp;author=S.%20Romeo&amp;volume=45&amp;issue=8&amp;publication_year=2013&amp;pages=619-624&amp;pmid=23333103&amp;doi=10.1016/j.dld.2012.12.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0013">
<span class="label">13.</span><cite>
Tilson S. G., Morell C. M., Lenaerts A.‐S., et al., “Modeling PNPLA3‐Associated NAFLD Using Human‐Induced Pluripotent Stem Cells,” Hepatology
74, no. 6 (2021): 2998–3017.
</cite> [<a href="https://doi.org/10.1002/hep.32063" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11497257/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34288010/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&amp;title=Modeling%20PNPLA3%E2%80%90Associated%20NAFLD%20Using%20Human%E2%80%90Induced%20Pluripotent%20Stem%20Cells&amp;author=S.%20G.%20Tilson&amp;author=C.%20M.%20Morell&amp;author=A.%E2%80%90S.%20Lenaerts&amp;volume=74&amp;issue=6&amp;publication_year=2021&amp;pages=2998-3017&amp;pmid=34288010&amp;doi=10.1002/hep.32063&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0014">
<span class="label">14.</span><cite>
Faccioli L. A. P., Cetin Z., Kocas‐Kilicarslan Z. N., et al., “Evaluation of Human Hepatocyte Drug Metabolism Carrying High‐Risk or Protection‐Associated Liver Disease Genetic Variants,” International Journal of Molecular Sciences
24, no. 17 (2023): 13406.
</cite> [<a href="https://doi.org/10.3390/ijms241713406" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10487897/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37686209/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=International%20Journal%20of%20Molecular%20Sciences&amp;title=Evaluation%20of%20Human%20Hepatocyte%20Drug%20Metabolism%20Carrying%20High%E2%80%90Risk%20or%20Protection%E2%80%90Associated%20Liver%20Disease%20Genetic%20Variants&amp;author=L.%20A.%20P.%20Faccioli&amp;author=Z.%20Cetin&amp;author=Z.%20N.%20Kocas%E2%80%90Kilicarslan&amp;volume=24&amp;issue=17&amp;publication_year=2023&amp;pages=13406&amp;pmid=37686209&amp;doi=10.3390/ijms241713406&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0015">
<span class="label">15.</span><cite>
Boeckmans J., Gatzios A., Schattenberg J. M., Koek G. H., Rodrigues R. M., and Vanhaecke T., “PNPLA3 I148M and Response to Treatment for Hepatic Steatosis: A Systematic Review,” Liver International
43, no. 5 (2023): 975–988.
</cite> [<a href="https://doi.org/10.1111/liv.15533" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36719059/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Liver%20International&amp;title=PNPLA3%20I148M%20and%20Response%20to%20Treatment%20for%20Hepatic%20Steatosis:%20A%20Systematic%20Review&amp;author=J.%20Boeckmans&amp;author=A.%20Gatzios&amp;author=J.%20M.%20Schattenberg&amp;author=G.%20H.%20Koek&amp;author=R.%20M.%20Rodrigues&amp;volume=43&amp;issue=5&amp;publication_year=2023&amp;pages=975-988&amp;pmid=36719059&amp;doi=10.1111/liv.15533&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0016">
<span class="label">16.</span><cite>
Sterne J. A. C., Savović J., Page M. J., et al., “RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials,” BMJ (Clinical Research Ed.)
366 (2019): l4898.</cite> [<a href="https://doi.org/10.1136/bmj.l4898" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31462531/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ%20(Clinical%20Research%20Ed.)&amp;title=RoB%202:%20A%20Revised%20Tool%20for%20Assessing%20Risk%20of%20Bias%20in%20Randomised%20Trials&amp;author=J.%20A.%20C.%20Sterne&amp;author=J.%20Savovi%C4%87&amp;author=M.%20J.%20Page&amp;volume=366&amp;publication_year=2019&amp;pages=l4898&amp;pmid=31462531&amp;doi=10.1136/bmj.l4898&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0017">
<span class="label">17.</span><cite>
Sterne J. A., Hernán M. A., Reeves B. C., et al., “ROBINS‐I: A Tool for Assessing Risk of Bias in Non‐Randomised Studies of Interventions,” BMJ (Clinical Research Ed.)
355 (2016): i4919.</cite> [<a href="https://doi.org/10.1136/bmj.i4919" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5062054/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27733354/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ%20(Clinical%20Research%20Ed.)&amp;title=ROBINS%E2%80%90I:%20A%20Tool%20for%20Assessing%20Risk%20of%20Bias%20in%20Non%E2%80%90Randomised%20Studies%20of%20Interventions&amp;author=J.%20A.%20Sterne&amp;author=M.%20A.%20Hern%C3%A1n&amp;author=B.%20C.%20Reeves&amp;volume=355&amp;publication_year=2016&amp;pages=i4919&amp;pmid=27733354&amp;doi=10.1136/bmj.i4919&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0018">
<span class="label">18.</span><cite>
Wells G. A., Shea B., O'Connell D., et al., “The Newcastle‐Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta‐Analyses,” accessed on 31 January 2025, <a href="https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp</a>.</cite>
</li>
<li id="liv70287-bib-0019">
<span class="label">19.</span><cite>
Murad M. H., Wang Z., Chu H., and Lin L., “When Continuous Outcomes Are Measured Using Different Scales: Guide for Meta‐Analysis and Interpretation,” BMJ (Clinical Research ed.)
364 (2019): k4817.</cite> [<a href="https://doi.org/10.1136/bmj.k4817" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6890471/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30670455/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ%20(Clinical%20Research%20ed.)&amp;title=When%20Continuous%20Outcomes%20Are%20Measured%20Using%20Different%20Scales:%20Guide%20for%20Meta%E2%80%90Analysis%20and%20Interpretation&amp;author=M.%20H.%20Murad&amp;author=Z.%20Wang&amp;author=H.%20Chu&amp;author=L.%20Lin&amp;volume=364&amp;publication_year=2019&amp;pages=k4817&amp;pmid=30670455&amp;doi=10.1136/bmj.k4817&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0020">
<span class="label">20.</span><cite>
Balduzzi S., Rücker G., and Schwarzer G., “How to Perform a Meta‐Analysis With R: A Practical Tutorial,” Evidence‐Based Mental Health
22, no. 4 (2019): 153–160.
</cite> [<a href="https://doi.org/10.1136/ebmental-2019-300117" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10231495/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31563865/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Evidence%E2%80%90Based%20Mental%20Health&amp;title=How%20to%20Perform%20a%20Meta%E2%80%90Analysis%20With%20R:%20A%20Practical%20Tutorial&amp;author=S.%20Balduzzi&amp;author=G.%20R%C3%BCcker&amp;author=G.%20Schwarzer&amp;volume=22&amp;issue=4&amp;publication_year=2019&amp;pages=153-160&amp;pmid=31563865&amp;doi=10.1136/ebmental-2019-300117&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0021">
<span class="label">21.</span><cite>
Sundbaum J. K., Baecklund E., Eriksson N., et al., “Genome‐Wide Association Study of Liver Enzyme Elevation in Rheumatoid Arthritis Patients Starting Methotrexate,” Pharmacogenomics
22, no. 15 (2021): 973–982.
</cite> [<a href="https://doi.org/10.2217/pgs-2021-0064" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34521259/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacogenomics&amp;title=Genome%E2%80%90Wide%20Association%20Study%20of%20Liver%20Enzyme%20Elevation%20in%20Rheumatoid%20Arthritis%20Patients%20Starting%20Methotrexate&amp;author=J.%20K.%20Sundbaum&amp;author=E.%20Baecklund&amp;author=N.%20Eriksson&amp;volume=22&amp;issue=15&amp;publication_year=2021&amp;pages=973-982&amp;pmid=34521259&amp;doi=10.2217/pgs-2021-0064&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0022">
<span class="label">22.</span><cite>
Guzman C. B., Duvvuru S., Akkari A., et al., “Coding Variants in PNPLA3 and TM6SF2 Are Risk Factors for Hepatic Steatosis and Elevated Serum Alanine Aminotransferases Caused by a Glucagon Receptor Antagonist,” Hepatology Communications
2, no. 5 (2018): 561–570.
</cite> [<a href="https://doi.org/10.1002/hep4.1171" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5944587/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29761171/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology%20Communications&amp;title=Coding%20Variants%20in%20PNPLA3%20and%20TM6SF2%20Are%20Risk%20Factors%20for%20Hepatic%20Steatosis%20and%20Elevated%20Serum%20Alanine%20Aminotransferases%20Caused%20by%20a%20Glucagon%20Receptor%20Antagonist&amp;author=C.%20B.%20Guzman&amp;author=S.%20Duvvuru&amp;author=A.%20Akkari&amp;volume=2&amp;issue=5&amp;publication_year=2018&amp;pages=561-570&amp;pmid=29761171&amp;doi=10.1002/hep4.1171&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0023">
<span class="label">23.</span><cite>
Capone F., De Vincentis A., Ferraro E., et al., “The PNPLA3 Rs738409 Variant Can Increase the Risk of Liver Toxicity in Multiple Sclerosis Patients Treated With Beta‐Interferon,” Clinical Neurology and Neurosurgery
197 (2020): 106166.
</cite> [<a href="https://doi.org/10.1016/j.clineuro.2020.106166" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32877766/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20Neurology%20and%20Neurosurgery&amp;title=The%20PNPLA3%20Rs738409%20Variant%20Can%20Increase%20the%20Risk%20of%20Liver%20Toxicity%20in%20Multiple%20Sclerosis%20Patients%20Treated%20With%20Beta%E2%80%90Interferon&amp;author=F.%20Capone&amp;author=A.%20De%20Vincentis&amp;author=E.%20Ferraro&amp;volume=197&amp;publication_year=2020&amp;pages=106166&amp;pmid=32877766&amp;doi=10.1016/j.clineuro.2020.106166&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0024">
<span class="label">24.</span><cite>
Feagins L. A., Flores A., Arriens C., et al., “Nonalcoholic Fatty Liver Disease: A Potential Consequence of Tumor Necrosis Factor‐Inhibitor Therapy,” European Journal of Gastroenterology &amp; Hepatology
27, no. 10 (2015): 1154–1160.
</cite> [<a href="https://doi.org/10.1097/MEG.0000000000000421" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5157831/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26148245/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=European%20Journal%20of%20Gastroenterology%20&amp;%20Hepatology&amp;title=Nonalcoholic%20Fatty%20Liver%20Disease:%20A%20Potential%20Consequence%20of%20Tumor%20Necrosis%20Factor%E2%80%90Inhibitor%20Therapy&amp;author=L.%20A.%20Feagins&amp;author=A.%20Flores&amp;author=C.%20Arriens&amp;volume=27&amp;issue=10&amp;publication_year=2015&amp;pages=1154-1160&amp;pmid=26148245&amp;doi=10.1097/MEG.0000000000000421&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0025">
<span class="label">25.</span><cite>
Pillai S., Duvvuru S., Bhatnagar P., et al., “The PNPLA3 I148M Variant Is Associated With Transaminase Elevations in Type 2 Diabetes Patients Treated With Basal Insulin Peglispro,” Pharmacogenomics Journal
18, no. 3 (2018): 487–493.
</cite> [<a href="https://doi.org/10.1038/tpj.2017.45" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29160303/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacogenomics%20Journal&amp;title=The%20PNPLA3%20I148M%20Variant%20Is%20Associated%20With%20Transaminase%20Elevations%20in%20Type%202%20Diabetes%20Patients%20Treated%20With%20Basal%20Insulin%20Peglispro&amp;author=S.%20Pillai&amp;author=S.%20Duvvuru&amp;author=P.%20Bhatnagar&amp;volume=18&amp;issue=3&amp;publication_year=2018&amp;pages=487-493&amp;pmid=29160303&amp;doi=10.1038/tpj.2017.45&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0026">
<span class="label">26.</span><cite>
Gutierrez‐Camino A., Martin‐Guerrero I., and Garcia‐Orad A., “PNPLA3 Rs738409 and Hepatotoxicity in Children With B‐Cell Acute Lymphoblastic Leukemia: A Validation Study in a Spanish Cohort,” Clinical Pharmacology and Therapeutics
102, no. 6 (2017): 906.
</cite> [<a href="https://doi.org/10.1002/cpt.756" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28744905/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20Pharmacology%20and%20Therapeutics&amp;title=PNPLA3%20Rs738409%20and%20Hepatotoxicity%20in%20Children%20With%20B%E2%80%90Cell%20Acute%20Lymphoblastic%20Leukemia:%20A%20Validation%20Study%20in%20a%20Spanish%20Cohort&amp;author=A.%20Gutierrez%E2%80%90Camino&amp;author=I.%20Martin%E2%80%90Guerrero&amp;author=A.%20Garcia%E2%80%90Orad&amp;volume=102&amp;issue=6&amp;publication_year=2017&amp;pages=906&amp;pmid=28744905&amp;doi=10.1002/cpt.756&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0027">
<span class="label">27.</span><cite>
Liu Y., Fernandez C. A., Smith C., et al., “Genome‐Wide Study Links PNPLA3 Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy,” Clinical Pharmacology and Therapeutics
102, no. 1 (2017): 131–140.
</cite> [<a href="https://doi.org/10.1002/cpt.629" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5511775/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28090653/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20Pharmacology%20and%20Therapeutics&amp;title=Genome%E2%80%90Wide%20Study%20Links%20PNPLA3%20Variant%20With%20Elevated%20Hepatic%20Transaminase%20After%20Acute%20Lymphoblastic%20Leukemia%20Therapy&amp;author=Y.%20Liu&amp;author=C.%20A.%20Fernandez&amp;author=C.%20Smith&amp;volume=102&amp;issue=1&amp;publication_year=2017&amp;pages=131-140&amp;pmid=28090653&amp;doi=10.1002/cpt.629&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0028">
<span class="label">28.</span><cite>
Yang W., Karol S. E., Hoshitsuki K., et al., “Association of Inherited Genetic Factors With Drug‐Induced Hepatic Damage Among Children With Acute Lymphoblastic Leukemia,” JAMA Network Open
5, no. 12 (2022): e2248803.
</cite> [<a href="https://doi.org/10.1001/jamanetworkopen.2022.48803" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9857512/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36580335/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Network%20Open&amp;title=Association%20of%20Inherited%20Genetic%20Factors%20With%20Drug%E2%80%90Induced%20Hepatic%20Damage%20Among%20Children%20With%20Acute%20Lymphoblastic%20Leukemia&amp;author=W.%20Yang&amp;author=S.%20E.%20Karol&amp;author=K.%20Hoshitsuki&amp;volume=5&amp;issue=12&amp;publication_year=2022&amp;pages=e2248803&amp;pmid=36580335&amp;doi=10.1001/jamanetworkopen.2022.48803&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0029">
<span class="label">29.</span><cite>
Harrison P. W., Amode M. R., Austine‐Orimoloye O., et al., “Ensembl 2024,” Nucleic Acids Research
52, no. D1 (2024): D891–D899.
</cite> [<a href="https://doi.org/10.1093/nar/gkad1049" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10767893/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37953337/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nucleic%20Acids%20Research&amp;title=Ensembl%202024&amp;author=P.%20W.%20Harrison&amp;author=M.%20R.%20Amode&amp;author=O.%20Austine%E2%80%90Orimoloye&amp;volume=52&amp;issue=D1&amp;publication_year=2024&amp;pages=D891-D899&amp;pmid=37953337&amp;doi=10.1093/nar/gkad1049&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0030">
<span class="label">30.</span><cite>
Bonkovsky H. L., Severson T., Nicoletti P., et al., “Genetic Polymorphisms Implicated in Nonalcoholic Liver Disease or Selected Other Disorders Have no Influence on Drug‐Induced Liver Injury,” Hepatology Communications
3, no. 8 (2019): 1032–1035.
</cite> [<a href="https://doi.org/10.1002/hep4.1382" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6671782/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31388624/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology%20Communications&amp;title=Genetic%20Polymorphisms%20Implicated%20in%20Nonalcoholic%20Liver%20Disease%20or%20Selected%20Other%20Disorders%20Have%20no%20Influence%20on%20Drug%E2%80%90Induced%20Liver%20Injury&amp;author=H.%20L.%20Bonkovsky&amp;author=T.%20Severson&amp;author=P.%20Nicoletti&amp;volume=3&amp;issue=8&amp;publication_year=2019&amp;pages=1032-1035&amp;pmid=31388624&amp;doi=10.1002/hep4.1382&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0031">
<span class="label">31.</span><cite>
Diogo D., Tian C., Franklin C. S., et al., “Phenome‐Wide Association Studies Across Large Population Cohorts Support Drug Target Validation,” Nature Communications
9, no. 1 (2018): 4285.</cite> [<a href="https://doi.org/10.1038/s41467-018-06540-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6191429/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30327483/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Communications&amp;title=Phenome%E2%80%90Wide%20Association%20Studies%20Across%20Large%20Population%20Cohorts%20Support%20Drug%20Target%20Validation&amp;author=D.%20Diogo&amp;author=C.%20Tian&amp;author=C.%20S.%20Franklin&amp;volume=9&amp;issue=1&amp;publication_year=2018&amp;pages=4285&amp;pmid=30327483&amp;doi=10.1038/s41467-018-06540-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0032">
<span class="label">32.</span><cite>
Larrieta‐Carrasco E., León‐Mimila P., Villarreal‐Molina T., et al., “Association of the I148M/PNPLA3 Variant With Elevated Alanine Transaminase Levels in Normal‐Weight and Overweight/Obese Mexican Children,” Gene
520, no. 2 (2013): 185–188.
</cite> [<a href="https://doi.org/10.1016/j.gene.2013.03.038" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23510779/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gene&amp;title=Association%20of%20the%20I148M/PNPLA3%20Variant%20With%20Elevated%20Alanine%20Transaminase%20Levels%20in%20Normal%E2%80%90Weight%20and%20Overweight/Obese%20Mexican%20Children&amp;author=E.%20Larrieta%E2%80%90Carrasco&amp;author=P.%20Le%C3%B3n%E2%80%90Mimila&amp;author=T.%20Villarreal%E2%80%90Molina&amp;volume=520&amp;issue=2&amp;publication_year=2013&amp;pages=185-188&amp;pmid=23510779&amp;doi=10.1016/j.gene.2013.03.038&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0033">
<span class="label">33.</span><cite>
Nogueira J. P. and Cusi K., “Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care,” Diabetes Spectrum
37, no. 1 (2024): 20–28.
</cite> [<a href="https://doi.org/10.2337/dsi23-0013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10877218/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38385099/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Spectrum&amp;title=Role%20of%20Insulin%20Resistance%20in%20the%20Development%20of%20Nonalcoholic%20Fatty%20Liver%20Disease%20in%20People%20With%20Type%202%20Diabetes:%20From%20Bench%20to%20Patient%20Care&amp;author=J.%20P.%20Nogueira&amp;author=K.%20Cusi&amp;volume=37&amp;issue=1&amp;publication_year=2024&amp;pages=20-28&amp;pmid=38385099&amp;doi=10.2337/dsi23-0013&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0034">
<span class="label">34.</span><cite>
Luukkonen P. K., Qadri S., Lehtimäki T. E., et al., “The PNPLA3‐I148M Variant Confers an Antiatherogenic Lipid Profile in Insulin‐Resistant Patients,” Journal of Clinical Endocrinology and Metabolism
106, no. 1 (2021): e300–e315.
</cite> [<a href="https://doi.org/10.1210/clinem/dgaa729" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33064150/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Endocrinology%20and%20Metabolism&amp;title=The%20PNPLA3%E2%80%90I148M%20Variant%20Confers%20an%20Antiatherogenic%20Lipid%20Profile%20in%20Insulin%E2%80%90Resistant%20Patients&amp;author=P.%20K.%20Luukkonen&amp;author=S.%20Qadri&amp;author=T.%20E.%20Lehtim%C3%A4ki&amp;volume=106&amp;issue=1&amp;publication_year=2021&amp;pages=e300-e315&amp;pmid=33064150&amp;doi=10.1210/clinem/dgaa729&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0035">
<span class="label">35.</span><cite>
Johnson S. M., Bao H., McMahon C. E., et al., “PNPLA3 Is a Triglyceride Lipase That Mobilizes Polyunsaturated Fatty Acids to Facilitate Hepatic Secretion of Large‐Sized Very Low‐Density Lipoprotein,” Nature Communications
15, no. 1 (2024): 4847.</cite> [<a href="https://doi.org/10.1038/s41467-024-49224-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11156938/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38844467/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Communications&amp;title=PNPLA3%20Is%20a%20Triglyceride%20Lipase%20That%20Mobilizes%20Polyunsaturated%20Fatty%20Acids%20to%20Facilitate%20Hepatic%20Secretion%20of%20Large%E2%80%90Sized%20Very%20Low%E2%80%90Density%20Lipoprotein&amp;author=S.%20M.%20Johnson&amp;author=H.%20Bao&amp;author=C.%20E.%20McMahon&amp;volume=15&amp;issue=1&amp;publication_year=2024&amp;pages=4847&amp;pmid=38844467&amp;doi=10.1038/s41467-024-49224-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0036">
<span class="label">36.</span><cite>
Cusi K., Sanyal A. J., Zhang S., et al., “Different Effects of Basal Insulin Peglispro and Insulin Glargine on Liver Enzymes and Liver Fat Content in Patients With Type 1 and Type 2 Diabetes,” Diabetes, Obesity &amp; Metabolism
18 (2016): 50–58.</cite> [<a href="https://doi.org/10.1111/dom.12751" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27723227/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes,%20Obesity%20&amp;%20Metabolism&amp;title=Different%20Effects%20of%20Basal%20Insulin%20Peglispro%20and%20Insulin%20Glargine%20on%20Liver%20Enzymes%20and%20Liver%20Fat%20Content%20in%20Patients%20With%20Type%201%20and%20Type%202%20Diabetes&amp;author=K.%20Cusi&amp;author=A.%20J.%20Sanyal&amp;author=S.%20Zhang&amp;volume=18&amp;publication_year=2016&amp;pages=50-58&amp;pmid=27723227&amp;doi=10.1111/dom.12751&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0037">
<span class="label">37.</span><cite>
En LiCho E., Ang C. Z., Quek J., et al., “Global Prevalence of Non‐Alcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus: An Updated Systematic Review and Meta‐Analysis,” Gut
72, no. 11 (2023): 2138–2148.
</cite> [<a href="https://doi.org/10.1136/gutjnl-2023-330110" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37491159/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gut&amp;title=Global%20Prevalence%20of%20Non%E2%80%90Alcoholic%20Fatty%20Liver%20Disease%20in%20Type%202%20Diabetes%20Mellitus:%20An%20Updated%20Systematic%20Review%20and%20Meta%E2%80%90Analysis&amp;author=E.%20En%20LiCho&amp;author=C.%20Z.%20Ang&amp;author=J.%20Quek&amp;volume=72&amp;issue=11&amp;publication_year=2023&amp;pages=2138-2148&amp;pmid=37491159&amp;doi=10.1136/gutjnl-2023-330110&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0038">
<span class="label">38.</span><cite>
Johansen R. F., Søndergaard E., Linnebjerg H., et al., “Attenuated Suppression of Lipolysis Explains the Increases in Triglyceride Secretion and Concentration Associated With Basal Insulin Peglispro Relative to Insulin Glargine Treatment in Patients With Type 1 Diabetes,” Diabetes, Obesity &amp; Metabolism
20, no. 2 (2018): 419–426.</cite> [<a href="https://doi.org/10.1111/dom.13087" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28817248/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes,%20Obesity%20&amp;%20Metabolism&amp;title=Attenuated%20Suppression%20of%20Lipolysis%20Explains%20the%20Increases%20in%20Triglyceride%20Secretion%20and%20Concentration%20Associated%20With%20Basal%20Insulin%20Peglispro%20Relative%20to%20Insulin%20Glargine%20Treatment%20in%20Patients%20With%20Type%201%20Diabetes&amp;author=R.%20F.%20Johansen&amp;author=E.%20S%C3%B8ndergaard&amp;author=H.%20Linnebjerg&amp;volume=20&amp;issue=2&amp;publication_year=2018&amp;pages=419-426&amp;pmid=28817248&amp;doi=10.1111/dom.13087&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0039">
<span class="label">39.</span><cite>
Cheng C., Jabri S., Taoka B. M., and Sinz C. J., “Small Molecule Glucagon Receptor Antagonists: An Updated Patent Review (2015–2019),” Expert Opinion on Therapeutic Patents
30, no. 7 (2020): 509–526.
</cite> [<a href="https://doi.org/10.1080/13543776.2020.1769600" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32552241/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Expert%20Opinion%20on%20Therapeutic%20Patents&amp;title=Small%20Molecule%20Glucagon%20Receptor%20Antagonists:%20An%20Updated%20Patent%20Review%20(2015%E2%80%932019)&amp;author=C.%20Cheng&amp;author=S.%20Jabri&amp;author=B.%20M.%20Taoka&amp;author=C.%20J.%20Sinz&amp;volume=30&amp;issue=7&amp;publication_year=2020&amp;pages=509-526&amp;pmid=32552241&amp;doi=10.1080/13543776.2020.1769600&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0040">
<span class="label">40.</span><cite>
Petersen K. F., Dufour S., Mehal W. Z., et al., “Glucagon Promotes Increased Hepatic Mitochondrial Oxidation and Pyruvate Carboxylase Flux in Humans With Fatty Liver Disease,” Cell Metabolism
36 (2024): 1–8.
</cite> [<a href="https://doi.org/10.1016/j.cmet.2024.07.023" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11612994/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39197461/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell%20Metabolism&amp;title=Glucagon%20Promotes%20Increased%20Hepatic%20Mitochondrial%20Oxidation%20and%20Pyruvate%20Carboxylase%20Flux%20in%20Humans%20With%20Fatty%20Liver%20Disease&amp;author=K.%20F.%20Petersen&amp;author=S.%20Dufour&amp;author=W.%20Z.%20Mehal&amp;volume=36&amp;publication_year=2024&amp;pages=1-8&amp;pmid=39197461&amp;doi=10.1016/j.cmet.2024.07.023&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0041">
<span class="label">41.</span><cite>
Harrison S. A., Browne S. K., Suschak J. J., et al., “Effect of Pemvidutide, a GLP‐1/Glucagon Dual Receptor Agonist, on MASLD: A Randomized, Double‐Blind, Placebo‐Controlled Study,” Journal of Hepatology
82, no. 1 (2025): 7–17.
</cite> [<a href="https://doi.org/10.1016/j.jhep.2024.07.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39002641/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Hepatology&amp;title=Effect%20of%20Pemvidutide,%20a%20GLP%E2%80%901/Glucagon%20Dual%20Receptor%20Agonist,%20on%20MASLD:%20A%20Randomized,%20Double%E2%80%90Blind,%20Placebo%E2%80%90Controlled%20Study&amp;author=S.%20A.%20Harrison&amp;author=S.%20K.%20Browne&amp;author=J.%20J.%20Suschak&amp;volume=82&amp;issue=1&amp;publication_year=2025&amp;pages=7-17&amp;pmid=39002641&amp;doi=10.1016/j.jhep.2024.07.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0042">
<span class="label">42.</span><cite>
Melander S. A., Kayed A., Andreassen K. V., Karsdal M. A., and Henriksen K., “OXM‐104, a Potential Candidate for the Treatment of Obesity, NASH and Type 2 Diabetes,” European Journal of Pharmacology
962 (2024): 176215.
</cite> [<a href="https://doi.org/10.1016/j.ejphar.2023.176215" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38056618/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=European%20Journal%20of%20Pharmacology&amp;title=OXM%E2%80%90104,%20a%20Potential%20Candidate%20for%20the%20Treatment%20of%20Obesity,%20NASH%20and%20Type%202%20Diabetes&amp;author=S.%20A.%20Melander&amp;author=A.%20Kayed&amp;author=K.%20V.%20Andreassen&amp;author=M.%20A.%20Karsdal&amp;author=K.%20Henriksen&amp;volume=962&amp;publication_year=2024&amp;pages=176215&amp;pmid=38056618&amp;doi=10.1016/j.ejphar.2023.176215&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0043">
<span class="label">43.</span><cite>
Luukkonen P. K., Porthan K., Ahlholm N., et al., “The PNPLA3 I148M Variant Increases Ketogenesis and Decreases Hepatic de Novo Lipogenesis and Mitochondrial Function in Humans,” Cell Metabolism
35, no. 11 (2023): 1887–1896.
</cite> [<a href="https://doi.org/10.1016/j.cmet.2023.10.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37909034/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell%20Metabolism&amp;title=The%20PNPLA3%20I148M%20Variant%20Increases%20Ketogenesis%20and%20Decreases%20Hepatic%20de%20Novo%20Lipogenesis%20and%20Mitochondrial%20Function%20in%20Humans&amp;author=P.%20K.%20Luukkonen&amp;author=K.%20Porthan&amp;author=N.%20Ahlholm&amp;volume=35&amp;issue=11&amp;publication_year=2023&amp;pages=1887-1896&amp;pmid=37909034&amp;doi=10.1016/j.cmet.2023.10.008&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0044">
<span class="label">44.</span><cite>
Cherubini A., Ostadreza M., Jamialahmadi O., et al., “Interaction Between Estrogen Receptor‐α and PNPLA3 p.I148M Variant Drives Fatty Liver Disease Susceptibility in Women,” Nature Medicine
29, no. 10 (2023): 2643–2655.</cite> [<a href="https://doi.org/10.1038/s41591-023-02553-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10579099/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37749332/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Medicine&amp;title=Interaction%20Between%20Estrogen%20Receptor%E2%80%90%CE%B1%20and%20PNPLA3%20p.I148M%20Variant%20Drives%20Fatty%20Liver%20Disease%20Susceptibility%20in%20Women&amp;author=A.%20Cherubini&amp;author=M.%20Ostadreza&amp;author=O.%20Jamialahmadi&amp;volume=29&amp;issue=10&amp;publication_year=2023&amp;pages=2643-2655&amp;pmid=37749332&amp;doi=10.1038/s41591-023-02553-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0045">
<span class="label">45.</span><cite>
Pan H. J., Chang H. T., and Lee C. H., “Association Between Tamoxifen Treatment and the Development of Different Stages of Nonalcoholic Fatty Liver Disease Among Breast Cancer Patients,” Journal of the Formosan Medical Association
115, no. 6 (2016): 411–417.
</cite> [<a href="https://doi.org/10.1016/j.jfma.2015.05.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26071793/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20the%20Formosan%20Medical%20Association&amp;title=Association%20Between%20Tamoxifen%20Treatment%20and%20the%20Development%20of%20Different%20Stages%20of%20Nonalcoholic%20Fatty%20Liver%20Disease%20Among%20Breast%20Cancer%20Patients&amp;author=H.%20J.%20Pan&amp;author=H.%20T.%20Chang&amp;author=C.%20H.%20Lee&amp;volume=115&amp;issue=6&amp;publication_year=2016&amp;pages=411-417&amp;pmid=26071793&amp;doi=10.1016/j.jfma.2015.05.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0046">
<span class="label">46.</span><cite>
Aslam S., Ameer S., Shabana N. A., and Ahmed M., “Pharmacogenetics of Induction Therapy‐Related Toxicities in Childhood Acute Lymphoblastic Leukemia Patients Treated With UKALL 2003 Protocol,” Scientific Reports
11 (2021): 23757.
</cite> [<a href="https://doi.org/10.1038/s41598-021-03208-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8660848/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34887513/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Scientific%20Reports&amp;title=Pharmacogenetics%20of%20Induction%20Therapy%E2%80%90Related%20Toxicities%20in%20Childhood%20Acute%20Lymphoblastic%20Leukemia%20Patients%20Treated%20With%20UKALL%202003%20Protocol&amp;author=S.%20Aslam&amp;author=S.%20Ameer&amp;author=N.%20A.%20Shabana&amp;author=M.%20Ahmed&amp;volume=11&amp;publication_year=2021&amp;pages=23757&amp;pmid=34887513&amp;doi=10.1038/s41598-021-03208-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0047">
<span class="label">47.</span><cite>
Kumar G. V. N., Hoshitsuki K., Rathod S., et al., “Mechanistic Studies of PEG‐Asparaginase‐Induced Liver Injury and Hepatic Steatosis in Mice,” Acta Pharmaceutica Sinica B
11, no. 12 (2021): 3779–3790.
</cite> [<a href="https://doi.org/10.1016/j.apsb.2021.11.022" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8727916/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35024306/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Acta%20Pharmaceutica%20Sinica%20B&amp;title=Mechanistic%20Studies%20of%20PEG%E2%80%90Asparaginase%E2%80%90Induced%20Liver%20Injury%20and%20Hepatic%20Steatosis%20in%20Mice&amp;author=G.%20V.%20N.%20Kumar&amp;author=K.%20Hoshitsuki&amp;author=S.%20Rathod&amp;volume=11&amp;issue=12&amp;publication_year=2021&amp;pages=3779-3790&amp;pmid=35024306&amp;doi=10.1016/j.apsb.2021.11.022&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0048">
<span class="label">48.</span><cite>
Choudhury A., Rajaram R., and Sarin S. K., “Acute‐On‐Chronic Liver Failure in Metabolic Dysfunction‐Associated Fatty Liver Disease Patients: A Disease Multiplier,” Hepatology International
18, no. 2 (2024): 941–958.
</cite> [<a href="https://doi.org/10.1007/s12072-024-10711-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39107615/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology%20International&amp;title=Acute%E2%80%90On%E2%80%90Chronic%20Liver%20Failure%20in%20Metabolic%20Dysfunction%E2%80%90Associated%20Fatty%20Liver%20Disease%20Patients:%20A%20Disease%20Multiplier&amp;author=A.%20Choudhury&amp;author=R.%20Rajaram&amp;author=S.%20K.%20Sarin&amp;volume=18&amp;issue=2&amp;publication_year=2024&amp;pages=941-958&amp;pmid=39107615&amp;doi=10.1007/s12072-024-10711-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0049">
<span class="label">49.</span><cite>
Ghabril M., Vuppalanchi R., and Chalasani N., “Drug‐Induced Liver Injury in Patients With Chronic Liver Disease,” Liver International
45, no. 3 (2025): e70019.
</cite> [<a href="https://doi.org/10.1111/liv.70019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11808633/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39927421/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Liver%20International&amp;title=Drug%E2%80%90Induced%20Liver%20Injury%20in%20Patients%20With%20Chronic%20Liver%20Disease&amp;author=M.%20Ghabril&amp;author=R.%20Vuppalanchi&amp;author=N.%20Chalasani&amp;volume=45&amp;issue=3&amp;publication_year=2025&amp;pages=e70019&amp;pmid=39927421&amp;doi=10.1111/liv.70019&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0050">
<span class="label">50.</span><cite>
Lammert C., Imler T., Teal E., and Chalasani N., “Patients With Chronic Liver Disease Suggestive of Nonalcoholic Fatty Liver Disease May be at Higher Risk for Drug‐Induced Liver Injury,” Clinical Gastroenterology and Hepatology
17, no. 13 (2019): 2814–2815.
</cite> [<a href="https://doi.org/10.1016/j.cgh.2018.12.013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30580093/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20Gastroenterology%20and%20Hepatology&amp;title=Patients%20With%20Chronic%20Liver%20Disease%20Suggestive%20of%20Nonalcoholic%20Fatty%20Liver%20Disease%20May%20be%20at%20Higher%20Risk%20for%20Drug%E2%80%90Induced%20Liver%20Injury&amp;author=C.%20Lammert&amp;author=T.%20Imler&amp;author=E.%20Teal&amp;author=N.%20Chalasani&amp;volume=17&amp;issue=13&amp;publication_year=2019&amp;pages=2814-2815&amp;pmid=30580093&amp;doi=10.1016/j.cgh.2018.12.013&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0051">
<span class="label">51.</span><cite>
Bessone F., Dirchwolf M., Rodil M. A., Razori M. V., and Roma M. G., “Review Article: Drug‐Induced Liver Injury in the Context of Nonalcoholic Fatty Liver Disease – A Physiopathological and Clinical Integrated View,” Alimentary Pharmacology &amp; Therapeutics
48, no. 9 (2018): 892–913.
</cite> [<a href="https://doi.org/10.1111/apt.14952" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30194708/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Alimentary%20Pharmacology%20&amp;%20Therapeutics&amp;title=Review%20Article:%20Drug%E2%80%90Induced%20Liver%20Injury%20in%20the%20Context%20of%20Nonalcoholic%20Fatty%20Liver%20Disease%20%E2%80%93%20A%20Physiopathological%20and%20Clinical%20Integrated%20View&amp;author=F.%20Bessone&amp;author=M.%20Dirchwolf&amp;author=M.%20A.%20Rodil&amp;author=M.%20V.%20Razori&amp;author=M.%20G.%20Roma&amp;volume=48&amp;issue=9&amp;publication_year=2018&amp;pages=892-913&amp;pmid=30194708&amp;doi=10.1111/apt.14952&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0052">
<span class="label">52.</span><cite>
Devarbhavi H. C. and Philips C. A., “Drug‐Induced Liver Injury in Patients With Underlying Liver Disease,” Clinical Liver Disease
23 (2024): e0189.
</cite> [<a href="https://doi.org/10.1097/CLD.0000000000000189" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11164011/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38860131/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20Liver%20Disease&amp;title=Drug%E2%80%90Induced%20Liver%20Injury%20in%20Patients%20With%20Underlying%20Liver%20Disease&amp;author=H.%20C.%20Devarbhavi&amp;author=C.%20A.%20Philips&amp;volume=23&amp;publication_year=2024&amp;pages=e0189&amp;pmid=38860131&amp;doi=10.1097/CLD.0000000000000189&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0053">
<span class="label">53.</span><cite>
Powell N. R., Liang T., Ipe J., et al., “Clinically Important Alterations in Pharmacogene Expression in Histologically Severe Nonalcoholic Fatty Liver Disease,” Nature Communications
14, no. 1 (2023): 1474.</cite> [<a href="https://doi.org/10.1038/s41467-023-37209-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10020163/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36927865/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Communications&amp;title=Clinically%20Important%20Alterations%20in%20Pharmacogene%20Expression%20in%20Histologically%20Severe%20Nonalcoholic%20Fatty%20Liver%20Disease&amp;author=N.%20R.%20Powell&amp;author=T.%20Liang&amp;author=J.%20Ipe&amp;volume=14&amp;issue=1&amp;publication_year=2023&amp;pages=1474&amp;pmid=36927865&amp;doi=10.1038/s41467-023-37209-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0054">
<span class="label">54.</span><cite>
Trépo E., Romeo S., Zucman‐Rossi J., and Nahon P., “PNPLA3 Gene in Liver Diseases,” Journal of Hepatology
65, no. 2 (2016): 399–412.
</cite> [<a href="https://doi.org/10.1016/j.jhep.2016.03.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27038645/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Hepatology&amp;title=PNPLA3%20Gene%20in%20Liver%20Diseases&amp;author=E.%20Tr%C3%A9po&amp;author=S.%20Romeo&amp;author=J.%20Zucman%E2%80%90Rossi&amp;author=P.%20Nahon&amp;volume=65&amp;issue=2&amp;publication_year=2016&amp;pages=399-412&amp;pmid=27038645&amp;doi=10.1016/j.jhep.2016.03.011&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0055">
<span class="label">55.</span><cite>
Li Y., Xing C., Tian Z., et al., “Genetic Variant I148M in PNPLA3 Is Associated With the Ultrasonography‐Determined Steatosis Degree in a Chinese Population,” BMC Medical Genetics
13, no. 1 (2012): 1–6.
</cite> [<a href="https://doi.org/10.1186/1471-2350-13-113" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3523076/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23176674/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Medical%20Genetics&amp;title=Genetic%20Variant%20I148M%20in%20PNPLA3%20Is%20Associated%20With%20the%20Ultrasonography%E2%80%90Determined%20Steatosis%20Degree%20in%20a%20Chinese%20Population&amp;author=Y.%20Li&amp;author=C.%20Xing&amp;author=Z.%20Tian&amp;volume=13&amp;issue=1&amp;publication_year=2012&amp;pages=1-6&amp;pmid=23176674&amp;doi=10.1186/1471-2350-13-113&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0056">
<span class="label">56.</span><cite>
Stender S., Kozlitina J., Nordestgaard B. G., et al., “Adiposity Amplifies the Genetic Risk of Fatty Liver Disease Conferred by Multiple Loci,” Nature Genetics
49, no. 6 (2017): 842–847.
</cite> [<a href="https://doi.org/10.1038/ng.3855" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5562020/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28436986/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Genetics&amp;title=Adiposity%20Amplifies%20the%20Genetic%20Risk%20of%20Fatty%20Liver%20Disease%20Conferred%20by%20Multiple%20Loci&amp;author=S.%20Stender&amp;author=J.%20Kozlitina&amp;author=B.%20G.%20Nordestgaard&amp;volume=49&amp;issue=6&amp;publication_year=2017&amp;pages=842-847&amp;pmid=28436986&amp;doi=10.1038/ng.3855&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70287-bib-0057">
<span class="label">57.</span><cite>
Jarasvaraparn C., Vilar‐Gomez E., Yates K. P., et al., “Age, BMI, and Type 2 Diabetes Modify the Relationship Between PNPLA3 and Advanced Fibrosis in Children and Adults With NAFLD,” Clinical Gastroenterology and Hepatology
22, no. 5 (2024): 1024–1036.
</cite> [<a href="https://doi.org/10.1016/j.cgh.2023.12.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11045318/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38145725/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20Gastroenterology%20and%20Hepatology&amp;title=Age,%20BMI,%20and%20Type%202%20Diabetes%20Modify%20the%20Relationship%20Between%20PNPLA3%20and%20Advanced%20Fibrosis%20in%20Children%20and%20Adults%20With%20NAFLD&amp;author=C.%20Jarasvaraparn&amp;author=E.%20Vilar%E2%80%90Gomez&amp;author=K.%20P.%20Yates&amp;volume=22&amp;issue=5&amp;publication_year=2024&amp;pages=1024-1036&amp;pmid=38145725&amp;doi=10.1016/j.cgh.2023.12.009&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><p>
<strong>Appendix S1:</strong> liv70287‐sup‐0001‐AppendixS1.zip.</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12375943/bin/LIV-45-0-s001.zip" data-ga-action="click_feat_suppl" class="usa-link">LIV-45-0-s001.zip</a><sup> (124.7KB, zip) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>Data sharing not applicable to this article as no new data were generated for this study. All data used to perform the meta‐analysis are available within the paper and Appendix <a href="#liv70287-supitem-0001" class="usa-link">S1</a>.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Liver International are provided here courtesy of <strong>Wiley</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1111/liv.70287"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/LIV-45-0.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (676.5 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12375943/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12375943/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12375943%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12375943/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12375943/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12375943/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40851509/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12375943/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40851509/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12375943/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12375943/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="LAZR1zb1YIMAX0UWVtrvv8DcwPar5pt4iXqpL0rU8U1yI2GSqxY9nDFZukTGNwAV">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
